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                                     1.0 ABSTRACT    
The objective of the present investigation was to prepare, evaluate and optimize
mucoadhesive  microspheres  of  Venlafaxine  HCl.  8  deferent  formulations  of
Venlafaxine HCl microspheres were prepared by emulsion solvent evaporation method
employing three polymers (EC, Eudragit RS 100, HPMC K4M) at different ratio using a
magnetic stirrer (800rpm). Acetone was used as solvent, light liquid paraffin as continues
system and Span 80 was used as emulsifier (1%w/v).the prepared microspheres were
evaluated for percentage yield, Particle size distribution, Angle of repose, Bulk density,
Drug  content,  Encapsulation  efficiency,  Shape  and  Surface  characterization,  In  vivo
wash–off test, In vitro dissolution studies and drug release mechanism was interpreted by
kinetic  models  and  formulation  was  optimized  by  f2  similarity  factor.  The  effect  of
polymer  on drug release and mucoadhesion was investigated.  The physico-  chemical
properties  was  satisfactory  for  prepared  formulations All  the  formulations  exhibited
anomalous (non-fickian transport) diffusion mechanism and follow first order kinetics.
The formulation F5 (-EC-750 mg Eudragit RS100 100 mg, HPMC K4M-300 mg,) was
selected  as  optimized  formulation;  with  93.08%  entrapment  efficiency,  good
mcoadhesive strength and 82.58% of drug release at 24th hours. Finally it is concluded
that with limited number of experiments an optimized formulation with target  release
and  good  mucoadhesion  can  be  developed  with  appropriate  statistical  experimental
design. 
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                                2.0 INTRODUCTION
The concept of drug delivery has been revolutionized. The studies has been made
to  lend  patient  derive  maximum benefits  of  drug.  The  drug  should  be  delivered  to
specific target sites at a rate and concentration that permit optimal therapeutic efficiency
while  reducing  side  effects  to  minimum.  Another  aspect  to  be  considered  in  drug
delivery is patient compliance during the drug delivery.
Between  1940’s  and  1960’s  the  concept  of  chemical  micro  encapsulation
technology is began as an alternative means of delivering drugs. In continued quest for
the more refined systems, 1980’s polymer technology came to be known at forefront.
Further the process of targeting and site specific delivery with absolute accuracy can be
achieved by attaching bioactive molecule to liposome,  bioerodable polymer,  implants
monoclonal  antibodies  and  various  particulate  carriers.  The  micro  particle  delivery
system are considerable and accepted as a reliable means to deliver drug to the target site
with specifically and to maintain the desired concentration at the site of interest without
unto wards effects.
For  many  drugs  a  well  designed  drug  delivery  system  is  as  important  as
pharmacological  activities  of  the  drug.  A  well  designed  drug  delivery  system  can
accurately deliver the drug to the side of action at desired rate and minimize its side
effects by reducing exposure of drug to other tissues1.
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2.1 DEPRESSION
What is depression? 2
           Depression is a prolonged or deep emotional sensation of sadness, being "blue",
or "down." Depressive feelings such as discouragement or sadness are perfectly normal
if they do not become too severe or last too long. Depression becomes a clinical problem
if a person’s mood becomes too depressed or if the episode lasts more than two weeks. If
there is any question about the severity of a person’s depression, he/she should have an
immediate evaluation by a mental health professional or a physician in order to rule out
suicidal intent.
2.1.1.  WHAT  ARE  THE  CHARACTERISTICS  ASSOCIATED  WITH
DEPRESSION?
Depression includes some of the following characteristics: 
• Feeling sad, blue, or down 
• Feeling unworthy 
• Feeling guilty 
• Feeling helpless 
• Loss of energy 
• Feeling restless 
• Feeling irritable 
• Feeling lethargic 
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• Fatigue 
• Increased sleep or decreased sleep 
• Insomnia or awakening during the night 
• Awakening earlier or later than normal 
• Loss of interest in hobbies, activities 
• Loss of interest in sex 
• Decreased ability to concentrate 
• Decreased ability to remember 
• Increase or decrease of appetite 
• Increase or decrease in weight 
• Thoughts of death 
• Thoughts of suicide 
     Also,  physical  symptoms  such  as  chronic  pain  or  a  lingering  illness  can
sometimes signal a depression. Similar to other illnesses, such as heart problems, asthma,
or diabetes, depression can become severe and disabling.
People with depression usually have problems with poor sleep, low mood and
appetite, loss of energy and interest or pleasure etc. It is a common illness, affecting 3%
of the population per year.  The main theory about why this happens is called “mono
amine hypothesis”. We know that serotonin and nor adrenaline in the brain are involved
with control of sleep wake, emotions, mood, arousal, drive and temperature.
Thus if a person has too little serotonin and nor adrenaline in the part of the brain
that controls mood this will produce too little activity and that part of the brain becomes
slower and less effective. This will lower mood.
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In  depression  it  is  known that  there  are  reduced  levels  of  serotonin  and  nor
adrenaline. These reduced levels lead to lowering of mood. The full reasons are not fully
known but stress may well play a part in causing this.
2.1.2  ETIOLOGY OF DEPRESSION 3
The etiology of  depression,  the mood disorder  most  frequently  studied,  is  far
from ideally understood. Many cases of depression are triggered by stressful life events,
yet  not  everyone  becomes  depressed  under  such  circumstances.  The  intensity  and
duration of these events, as well as each individual’s genetic endowment, coping skills
and reaction, and social support network contribute to the likelihood of depression. That
is why depression and many other mental disorders are broadly described as the product
of  a  complex  interaction  between  biological  and  psychosocial  factors.  The  relative
importance of biological and psychosocial factors may vary across individuals and across
different types of depression.
This section of  the chapter  describes  the biological,  genetic,  and psychosocial
factors—such as cognition, personality,  and gender—that correlate with, or predispose
to,  depression.  The discussion of  genetic  factors  also incorporates  the  latest  findings
about bipolar disorder. Genes are implicated even more strongly in bipolar disorder than
they are in major depression, galvanizing a worldwide search to identify chromosomal
regions where genes  may be located and ultimately to pinpoint the genes themselves
(NIMH, 1998).
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2.1.3 DIAGNOSIS AND TREATMENT 4
Diagnosis  and treatment  of  the sever  anxiety disorders  has advanced recently
.Stimulated  by  the  discovery  that  selective  serotonin-reuptake  inhibitors  which  are
effective antidepressants also are powerful anti anxiety agents. Disorders include panic
agoraphobia;  social  and other  phobias,  generalized  anxiety and obsessive-compulsive
disorder all appear to be responsive to treatment with serotonin reuptake inhibitors.
The process of development for DSM-IV published by the APA in 1994, was
guided  by specific  reviews based upon new empirical  evidence  for  diagnosis.  In  the
classification of mood disorders, the major change in DSM-IV from DSM-III and DSM-
III-R  includes  a  listing  of  nine  criterion  symptoms  of  which  dysphoric  mood  or
depressed mood or loss of interest or pleasure must be present nearly every day most of
the day during a 2-week period. Four additional symptoms associated with a primary
depressed mood or loss of interest must be met. Previously, in DSM-III,  the criteria of
depressed mood or loss of interest were listed as criterion A and four of eight additional
symptoms were required for the diagnosis of major depressive episode.
More  substantial  changes  were  made in  the diagnostic  criteria  for  Dysthymic
Disorder. In DSM-III,  the diagnosis of depressive mood required 2 years duration and
three of 13 criteria in the absence of psychotic symptoms or another pre-existing mental
disorder. In DSM-IV, depressed mood most of the day for at least 2 years was required
in the presence of two of six criterion symptoms. The exclusion criteria again included a
chronic psychotic disorder but other common psychiatric disorders did not pose specific
exclusion criteria in diagnosis. In DSM-IV, clinically significant distress or impairment
in social, occupational or other important areas in functioning was required. In general,
DSM-IV permitted more co-occurring diagnoses to be listed on Axis I without specific
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exclusion  factors.  An  additional  difference  in  DSM-IV  represents  the  diagnosis  of
secondary mood disorders, characterized as Mood Disorder Due to a General Medical
Condition or Substance- Induced Mood Disorder, in which the disturbance in mood is
judged  to  be  a  direct  effect  of  a  General  medical  condition  or  due  to  substance
intoxication, withdrawal or other medication use. The clinician then specifically notes
the name of the general medical Condition on Axis I or the specific substance involved
in intoxication or withdrawal
Treatment  of Depression.
The  three  for  a  fuller  discussion  of  standard,  rarer  and  more  experimental
treatments, see most commonly indicated treatments for depression are psychotherapy,
medication, and electroconvulsive therapy. Psychotherapy is the treatment of choice for
people under 18, while electroconvulsive therapy is only used as a last resort in severe
cases or in emergencies. Patients are usually assessed and managed as outpatients, and
only admitted to an inpatient mental health unit if they are considered to pose a risk to
themselves or others.
1 Psychotherapy
Albert Ellis invented Rational Emotive Behavior Therapy, the earliest form of 
Cognitive Behavioral Therapy.
There are a number of different psychotherapies for depression, which may be
provided to individuals or groups. Psychotherapy can be delivered by a variety of mental
health  professionals,  including  psychotherapists,  psychiatrists,  psychologists,  clinical
social  workers,  counselors,  and  psychiatric  nurses.  With  more  complex  and  chronic
forms of depression the most effective treatment is often considered to be a combination
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of medication and  psychotherapy.  In  people  under  18,  medication  is  offered  only in
conjunction with psychotherapy, not as a first line agent. 
The most studied form of psychotherapy for depression is  cognitive behavioral
therapy (CBT), thought to work by teaching clients to learn a set of useful cognitive and
behavioral skills. Earlier research suggested that cognitive-behavioral therapy was not as
effective as antidepressant medication; however,  more recent research suggests that it
can perform as well as antidepressants in patients with moderate to severe depression.
For  the  treatment  of  adolescent  depression,  CBT  performed  no  better  than
placebo,  and  significantly  worse  than  the  antidepressant  fluoxetine.  Combining
fluoxetine  with  CBT  appeared  to  bring  no  additional  benefit  or,  at  the  most,  only
marginal benefit.
Two  randomized,  controlled  trials  of  mindfulness-based  cognitive  therapy
(MBCT),  which  includes  elements  of  meditation,  have  been  reviewed.  MBCT  was
significantly more effective than "usual care" for the prevention of recurrent depression
in patients who had had three or more depressive episodes. According to the review, the
"usual  care"  did  not  include  antidepressant  treatment  or  any psychotherapy,  and  the
improvement observed may have reflected the non-specific or placebo effects.
Interpersonal psychotherapy focuses on the social and interpersonal triggers that
may cause depression. There is evidence that it is an effective treatment for depression.
Here, the therapy takes a structured course with a set number of weekly sessions (often
12) as in the case of CBT; however the focus is on relationships with others. Therapy can
be used to help a person develop or improve interpersonal skills in order to allow him or
her to communicate more effectively and reduce stress.
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Psychoanalysis, a school of thought founded by Sigmund Freud that emphasizes
the resolution of unconscious mental conflicts, is used by its practitioners to treat clients
presenting with major depression. A more widely practiced, eclectic technique, called
psychodynamic psychotherapy, is loosely based on psychoanalysis and has an additional
social  and  interpersonal  focus.  In  a  meta-analysis  of  three  controlled  trials,
psychodynamic psychotherapy was found to be as effective as medication for mild to
moderate depression.
2   Electroconvulsive therapy
Electroconvulsive therapy (ECT) is a procedure where seizures are electrically
induced in anesthetized patients for therapeutic effect. ECT is most often used as a "last
resort" (from the perspective of hospital psychiatrists) for severe major depression which
has not responded to trials of antidepressant or, less often, psychotherapy or supportive
interventions. It  has a quicker effect than antidepressant therapy, and thus may be the
treatment of choice in emergencies such as catatonic depression where the patient has
ceased  oral  intake  of  fluid  or  nutrients,  or  where  there  is  severe  suicidality.  Some
evidence suggests it is the most effective treatment for depression in the short-term and
one study without  a  comparison group  or  assessment  of  additional  treatments  given,
suggested remission is related to improved self-rated quality of life in both the short-term
(correlated with the degree of amnesia) and after six months. However, ECT has been
found to have much lower remission rates in real-world practice and on its own does not
have a sustained benefit  as nearly everyone relapses.  The relapse rate  in the first  six
months may be reduced by the use of psychiatric medications or further ECT (though the
latter is not recommended by some authorities, such as NICE), but remains high. Short-
term memory loss, disorientation, headache and other adverse effects are common, as are
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long-term memory and other neurocognitive deficits, which may persist. The American
Psychiatric  Association and the National  Institute  for  Health  and Clinical  Excellence
have  concluded  that  the  evidence  they  had  suggested  that  the  procedure,  when
administered  according  to  their  standards  and without  complications,  does  not  cause
brain damage in adults.
3 Other methods of treatment
Several other less widely used treatments have been officially approved either in
the US or Europe. St. John's wort extract is available as a prescription antidepressant in
several European countries, but is classified as an herbal supplement and sold over the
counter  in  the  US.  A  systematic  meta-analysis  of  37  trials  conducted  by  Cochrane
Collaboration  indicated  statistically  significant  weak-to-moderate  effect  compared  to
placebo. The same meta-analysis found that St John's wort efficacy for major depression
is not significantly different from that of prescription antidepressants. NCCAM and other
NIH-affiliated organizations hold that St. John's wort has minimal or no effects beyond
placebo in the treatment of major depression, based primarily on one study with negative
outcome  conducted  by  NCCAM.  S-Adenosyl  methionine  (SAM-e)  is  another  drug
available as a prescription antidepressant in Europe, and as an over-the-counter dietary
supplement in the US. Fairly strong evidence from 16 clinical trials indicates it to be as
effective as standard antidepressant medication for the treatment of major depression.
In repetitive trans-cranial magnetic stimulation (rTMS), powerful magnetic fields
are applied to the brain from outside the head. Multiple controlled studies support the use
of this method in treatment-resistant depression; it has been approved for this indication
in Europe, Canada and Australia, but not in the US. A 2008 meta-analysis based on 32
trials  found  a  robust  effect  of  this  method  on  depression,  and  it  appeared  similarly
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effective  for  both  uncomplicated  depression  and  depression  resistant  to  medication.
However, it was inferior to ECT in a side-by-side randomized trial.
A number of other therapeutic approaches have sometimes been used although
they are not officially sanctioned. Bright light therapy has been found to be an effective
treatment  for  the  winter  depression  produced  by  seasonal  affective  disorder.  In  the
analysis commissioned by APA it appeared to be moderately effective for non-seasonal
depression,  although  it  did  not  improve  the  outcome when  combined  with  standard
antidepressant  therapy.  Another  meta-analysis  of  light  therapy  for  non-seasonal
depression  conducted  by  Cochrane  Collaboration  studied  a  different  set  of  trials,  in
which  light  was  used  mostly  as  an  addition  to  medication  or  sleep  deprivation.  A
moderate statistically significant effect was found, although it disappeared if a different
statistical technique was used. Both analyses noted poor quality of most studies and their
small size and urged caution in the interpretation of their results. The short duration (1–2
weeks)  of  most  trials  makes  it  unclear  whether  the  effect  of  light  therapy  could  be
sustained in the longer term.
Many people who regularly exercise have an intuitive sense that the activity is
beneficial  to  their  mood states.  Some empirical  support  for  this comes from a Duke
University study, in which exercise, when used in conjunction with medication by non-
suicidal patients, had beneficial effects in preventing the return of depression. Patients
who completed 30 minutes of brisk exercise at least three times a week were found to
have a significantly lower incidence of relapse.
Epidemiological  studies  indicate  that  the  countries  with  high  consumption  of
omega-3 fatty acids may have a lower rate of depression. For major depression, omega-3
fatty acid have been studied primarily as an adjunct to antidepressant therapy. A meta-
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analysis  of  eight  such  trials  indicated  a  statistically  significant  superiority  of
combinations with omega-3 fatty acids over single antidepressants; however, the authors
warned  that,  due  to  multiple  problems  with  these  trials,  a  reliable  conclusion  was
difficult  to  achieve.  Tryptophan  and  5-hydroxytryptophan  (5-HTP)  are  obvious
candidates for antidepressants, because they are metabolic precursors for serotonin. The
Cochrane  Collaboration  analyzed  the  combined  set  of  trials  for  the  both  of  these
treatments. Although the results appeared to indicate better than placebo efficacy, only
two out of 108 trials were of sufficient quality to be included in the analysis.
Several other treatments deserve a brief mention. Acupuncture has been tried, but
a 2004 Cochrane Review concluded that  there  was insufficient  evidence  to judge its
effectiveness for managing depression. Deep brain stimulation is currently in a very early
investigational stage, and data are available only from a handful of case studies. Vagus
nerve  stimulation  is  an  FDA-approved  therapy  for  treatment-resistant  depression.
However, the support for this method comes mainly from open-label trials and the only
large double-blind trial yielded inconclusive results
2.1.4  ANTI DEPRESSANTS 5,6
These are drugs which can elevate mood in depressive illness. Practically
all antidepressants  affect  monoaminergic transmission in the brain in one way or the
other and  many of them have other associated properties The treatment of depression
relies on a varied group of anti  depressant therapeutic agents in part because clinical
depression  is  a  complex  syndrome  of  widely  varying  severity.  The  first  agent  used
successfully  were  tricyclic  antidepressants   which  elicit  a  wide  range  of  neuro
pharmacological effects in addition to their presumed primary action .i.e. inhibiting nor
epinephrine  uptake  into  nerve  endings  and  thus  leading  to  sustained  facilitation  of
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noradrenergic and perhaps serotonergic function in the brain. Inhibitors of monoamine
oxidase, which increases the brain concentration of many amines, also have been used.
Particularly  over  the  past  two  decades  a  large  number  of  anti  depressants  with  an
assortment  of  effects  of  reuptake  /metabolism of  biogenic  amine  and  on  pre  /post-
junctional  aminergic/cholinergic  receptors  have  become  available  so  that  a  cogent
classification is difficult. The following working classification may be adopted(Table 1). 
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                                                             Table 1
NAME OF DRUG DOSE in mg MECHANISM OF ACTION
Moclobamide 300-600 Reversible inhibitors of MAO-A
Clorgyline 300-600 Reversible inhibitors of MAO-A
Imipramine 50-200 Tri cyclic Antidepressant inhibits NA+5-HT reuptake
Amitriptyline 50-200 Tri cyclic Antidepressant inhibits NA+5-HT reuptake
Trimipramine 50-150 Tri cyclic Antidepressant inhibits NA+5-HT reuptake
Doxepin 50-150 Tri cyclic Antidepressant inhibits NA+5-HT reuptake
Dothiepin 50-150 Tri cyclic Antidepressant inhibits NA+5-HT reuptake
Clomipramine 50-150 Tri cyclic Antidepressant inhibits NA+5-HT reuptake
Desipramine 50-200 Tri cyclic Antidepressant inhibits NA reuptake
Nortriptyline 50-150 Tri cyclic Antidepressant inhibits NA reuptake
Amoxapine 100-300 Tri cyclic Antidepressant inhibits NA reuptake
Fluoxetine 20-60 Selective serotonin reuptake inhibitors
Fluoxamine 50-200 Selective serotonin reuptake inhibitors
Paroxetine 20-50 Selective serotonin reuptake inhibitors
Setraline 50-200 Selective serotonin reuptake inhibitors
Citalopram 20-40 Selective serotonin reuptake inhibitors
Venlafaxine 75-150
Serotonin/no
r adrenaline
reuptake
inhibitors
Trazodone 50-200 Weak inhibitors of 5-HT reuptake and α-blocker
Mianserin 30-100 Presynaptic α2-blocker
Mirtazapine 15-45 Presynaptic α2-blocker
Tianeptine 20-60 5-HT reuptake inhibitor
2.1.4.1 SOME KEY FACTS ABOUT ANTIDEPRESSANTS 5
• The symptoms of depression are caused by an imbalance of chemicals in the 
brain probably reduced levels of serotonin and nor adrenaline.
• Anti depressants help correct this imbalance in the brain.
• Antidepressants are not  stimulants
• They do not alter personality
• They are not additive and are not habit forming
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• They do not loose their effect if you keep taking them
There  are  lots  of  theories  about  how depression occurs  e.g.  genetics,  how the  brain
develops, stress etc. There are many in fact be many cause and in each person there may
a combination of these. Stress may in fact cause changes in the brain which then result in
reduced levels of serotonin and nor adrenaline. Transmitters other than much serotonin
and nor adrenaline are probably also involved.   
2.1.4.2 ANTIDEPRESSANTS ACTION 
 If  too little serotonin produces the symptoms of depression the correcting this
should helps to reduce symptoms. One way of doing this is to block the reuptake of
transmitters.  This  is  just  what  these  antidepressants  do.  They  block  the  reuptake  of
serotonin and nor adrenaline, so the next time an impulse comes along, there is more
transmitters stronger message is passed, and activity in that part of the brain is increased.
The important thing to remember is that tricyclic and related antidepressants probably
mainly work by correcting the effect of having too little transmitter. They are not just
stimulants
2.2  SUSTAINED RELEASE DRUG THERAPY 7,5
         Conventional  dosage forms include solutions,  suspensions,  capsules,  tablets,
emulsions,  aerosols,  foams,  ointments  and  suppositories.  These  dosage  forms can  be
considered to release their active ingredients into an absorption pool immediately. This is
illustrated in the following simple kinetic scheme:
Dosage           Kr             Absorption          Ka          Target                Ke
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form          drug release        Pool          absorption      Area             Elimination
The absorption pool represents a solution of the drug at the site of absorption, and
the terms Kr, Ka and Ke are first – order rate constants for drug release, absorption and
overall  elimination, respectively.  Immediate  release from a conventional  dosage form
implies that Kr>>>Ka or that observation of drug across a biological membrane, such as
the intestinal epithelium, is the rate-limiting step in delivery of the drug to its target area.
For non immediate – release dosage form, Kr<<<Ka, that is, release of drug from
the dosage form is the rate - limiting step. This causes the above kinetic to reduce the
following:
                            Dosage form         Kr             Target area        Ke
                                                     Drug release                        Elimination
To overcome the potential problems associated with conventional drug therapy, 
modified release/ non-immediate-release delivery systems were developed and may be 
divided into four categories:
1. Delayed release
2. Sustained release
 Controlled release
 Prolonged release
3. Site-specific release
4. Receptor release
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2.3. MUCOADHESIVE MICROSPHERES
Mucoadhesive microspheres include micro particles and microcapsules (having a
core  of  the  drug)  of  1-1000  µm  in  diameter  and  consisting  either  entirely  of  a
mucoadhesive polymer or having an outer coating of it, respectively8. Microspheres, in
general, have the potential to be used for targeted and controlled release drug delivery;
but coupling of mucoadhesive properties to microspheres has additional advantages, e.g.
efficient absorption and enhanced bioavailability of the drugs due to a high surface to
volume ratio, a much more intimate contact with the mucus layer, specific targeting of
drug to the absorption site achieved by anchoring plant lectins9, bacterial adhesions10 and
antibodies11, etc. on the surface of the microspheres. Mucoadhesive microspheres can be
tailored to adhere to any mucosal tissue including those found in eye, nasal cavity and
urinary and gastrointestinal tract, thus offering the possibilities of localized as well as
systemic controlled release of drugs. Application of mucoadhesive microspheres to the
mucosal tissues of ocular cavity, gastric and colonic epithelium is used for administration
of drugs for localized action. Prolonged release of drugs and a reduction in frequency of
drug administration to the ocular cavity can highly improve the patient compliance12. The
latter  advantage  can also be obtained for  drugs administered  intra-nasally due  to  the
reduction in mucociliary clearance of drugs adhering to nasal mucosa13. Microspheres
prepared with mucoadhesive and bioerodible polymers undergo selective uptake by the
M cells of Payer patches in gastrointestinal (GI) mucosa14. This uptake mechanism has
been used for the delivery of protein and peptide drugs,  antigens for vaccination and
plasmid DNA for gene therapy. Moreover, by keeping the drugs in close proximity to
their absorption window in the GI mucosa. The mucoadhesive microspheres improve the
absorption  and  oral  bioavailability  of  drugs  like  furosemide15 and  riboflavin16.  The
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concept of a non-invasive single shot vaccine, by means of mucosal immunization, offers
controlled  release  of  antigens  and  thus  forms  another  exquisite  application  of
mucoadhesive microspheres17
2.3.1  POLYMERS USED FOR MUCOADHESIVE MICROSPHERES
The  type  of  polymers  used  to  prepare  them influences  the  properties  of  the
mucoadhesive  microspheres,  based  on  their  surface  characteristics,  force  of
mucoadhesion, release pattern of the drug, and clearance. Suitable polymers that can be
used  to  form  mucoadhesive  microspheres  include  soluble  and  insoluble,  non-
biodegradable and biodegradable polymers. These can be hydrogels or thermoplastics,
homopolymeres, copolymers or blends, natural or synthetic polymers. 
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2.3.2 CLASSIFICATION OF POLYMERS
(a) Hydrophilic Polymers 
These are the water-soluble polymers that swell indefinitely in contact with water
and  eventually  undergo  complete  dissolution,  Eg: Methylcellulose,  hydroxyethyl
cellulose, hydroxy propyl methyl cellulose, sodium carboxy methyl cellulose, carbomers,
chitosan and plant gums etc.
(b) Hydrogels
These are water swellable materials, usually a cross-link polymer with limited
swelling capacity, eg: Poly acrylic acid co acrylamide copolymers, sodium alginate, guar
gum and modified guar gum etc.
(c) Thermoplastic Polymers 
These polymers include the non-erodible neutral polystyrene and semi crystalline
bioerodible polymers, which generate the carboxylic acid groups as they degrade,  Eg:
polyanhydrides and polylactic acid. Various synthetic polymers used in mucoadhesive
formulations  include  polyvinyl  alcohol,  polyamides,  polycarbonates,  polyalkylene
glycols,  polyvinyl  ethers,  esters,  halides, polymethacrylic  acid, polymethylmethacrylic
acid, methylcellulose, hydroxypropyl cellulose, and hydroxypropyl methylcellulose and
sodium carboxymethylcellulose. Various biocompatible polymers used in mucoadhesive
formulations  include  cellulose-based  polymers,  ethylene  glycol  polymers  and  its
copolymers,  oxyethylene polymers,  polyvinyl  alcohol, polyvinyl  acetate  and esters of
haluronicacid. Various biodegradable polymers used in mucoadhesive formulations are
poly  lactides,  poly  glycolides,  poly  lactide-co-glycolides,  polycaprolactones,  and
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polyalkyl  cyanoacrylate.  Polyorthoesters,  polyphosphoesters,  polyanhydrides  and
polyphosphazenes are the recent additions to the polymers.
2.3.3 METHODS OF PREPARATON OF MUCOADHESIVE MICROSPHERES
Mucoadhesive microspheres can be prepared using any of the following techniques.
(a) Solvent Evaporation 
It is the most extensively used method of microencapsulation, first described by
Ogawa et al.18 A buffered or plain aqueous solution of the drug (may contain a viscosity
building or stabilizing agent) is added to an organic phase consisting of the polymer
solution in solvents like dichloromethane (or ethyl acetate or chloroform) with vigorous
stirring to form the primary water in oil emulsion. This emulsion is then added to a large
volume  of  water  containing  an  emulsifier  like  PVA  or  PVP  to  form  the  multiple
emulsions (w/o/w). The double emulsion, so formed, is then subjected to stirring until
most of the organic solvent evaporates,  leaving solid microspheres. The Microspheres
can then be  washed,  centrifuged  and  lyophilize to  obtain the free  flowing  and dried
microspheres.
(b) Hot Melt Microencapsulation 
This method was first used by Mathiowitz and Langer19 to prepare microspheres
of polyanhydride copolymer of poly [bis (p-carboxy phenoxy) propane anhydride] with
sebacic  acid.  In  this  method,  the  polymer  is  first  melted  and then  mixed with solid
particles of the drug that have been sieved to less than 50 µm. The mixture is suspended
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in  a  non-miscible  solvent  (like  silicone  oil),  continuously stirred,  and heated  to  5°C
above the melting point of the polymer. Once the emulsion is stabilized, it is cooled until
the polymer  particles  solidify.  The resulting microspheres  are  washed by decantation
with petroleum ether. The primary objective for developing this method is to develop a
microencapsulation process suitable for the water labile polymers,  e.g.  polyanhydrides.
Microspheres with diameter of 1-1000 µm can be obtained and altering the stirring rate
can easily control the size distribution. The only disadvantage of this method is moderate
temperature to which the drug is exposed.
(c) Solvent Removal 
It is a non-aqueous method of microencapsulation, particularly suitable for water
labile  polymers  such  as  the  ployanhydrides.  In  this  method,  drug  is  dispersed  or
dissolved  in  a  solution  of  the  selected  polymer  in  a  volatile  organic  solvent  like
methylene chloride. This mixture is then suspended in silicone oil containing span 80
and methylene chloride20. After pouring the polymer solution into silicone oil, petroleum
ether is added and stirred until solvent is extracted into the oil solution. The resulting
Microspheres can then be dried in vacuum. 
(d) Hydro gel Micro spheres 
Microspheres  made  of  gel-type  polymers,  such  as  alginate,  are  produced  by
dissolving the polymer in an aqueous solution, suspending the active ingredient in the
mixture and extruding through a precision device, producing micro droplets which fall
into a hardening bath that is slowly stirred. The hardening bath usually contains calcium
chloride  solution,  whereby  the  divalent  calcium  ions  crosslink  the  polymer  forming
gelled microspheres. The method involves an “all-aqueous” system and avoids residual
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solvents in microspheres.  Lim and Moss21 developed this method for encapsulation of
live cells, as it does not involve harsh conditions, which could kill  the cells. Coating
them with polycationic polymers, like polylysine after fabrication, can further modify the
surface of these microspheres.  The particle size of microspheres can be controlled by
using various size extruders or by varying the polymer solution flow rates.
(e) Spray Drying 
In this process, the drug may be dissolved or dispersed in the polymer solution
and  spray  dried.  The  quality  of  spray-dried  microspheres  can  be  improved  by  the
addition of plasticizers, e.g. citric acid, which promote polymer coalescence on the drug
particles  and  hence  promote  the  formation  of  spherical  and  smooth  surfaced
microspheres. The size of microspheres can be controlled by the rate of spraying, the
feed rate of polymer drug solution, nozzle size, and the drying temperature. This method
of micro encapsulation is particularly less dependent on the solubility characteristics of
the drug and polymer and is simple, reproducible, and easy to scale up22
(f) Phase Inversion Micro encapsulation
The process involves addition of drug to a dilute solution of the polymer (usually
1-5%, w/v in methylene chloride). The mixture is poured into an unstirred bath of strong
non-solvent (petroleum ether) in a solvent to non-solvent ratio of 1: 100, resulting in the
spontaneous production of microspheres in the size range of 0.5-5.0 mm can then be
filtered, washed with petroleum ether and dried with air23. This simple and fast process of
micro encapsulation involves relatively little loss of polymer and drug.
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2.3.4 EVALUATION OF MUCOADHESIVE MICROSPHERES
The  best  approach  to  evaluate  mucoadhesive  microspheres  is  to  evaluate  the
effectiveness of mucoadhesive polymer to prolong the residence time of drug at the site
absorption, thereby increasing absorption and bioavailability of the drug. The methods
used to evaluate mucoadhesive microspheres include the following.
2.3.4.1   Measurement of Adhesive Strength
The quantification of the mucoadhesive forces between polymeric microspheres
and the mucosal tissue is a useful indicator for evaluating the mucoadhesive strength of
microspheres.  In vitro  techniques have been used to test  the polymeric  microspheres
against a variety of synthetic and natural mucus, frozen and freshly excised tissue  etc.
The different in vitro methods include the following.
(a) Tensile Stress Measurement (Wilhelmy Plate Technique)
The  wilhelmy  plate  technique  is  traditionally  used  for  the  measurement  of
dynamic contact angles and involves the use of a microdensitometer or microbalance.
The  CAHN  dynamic  contact  angle  analyzer  (model  DCA  322,  CAHN  instruments,
Cerritos) has been modified to perform adhesive micro force measurements. The DCA
322 system consists of an IBM compatible computer and microbalance assembly24. The
microbalance  unit  consists  of stationary sample and tare loops and a motor powered
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translation stage.  The instrument  measures  the  mucoadhesive  force  between  mucosal
tissue and a single microsphere mounted on a small diameter metal wire suspended from
the sample loop in microtesiometer25. The tissue, usually rat jejunum, is mounted within
the  tissue  chamber  containing  Dulbecco’s  phosphate  buffered  saline  containing  100
mg/dl glucose and maintained at the physiologic temperature. The chamber rests on a
mobile platform, which is raised until the tissue comes in contact with the suspended
microsphere. The contact is held for 7 minutes, at which time the mobile stage is lowered
and the resulting force of adhesion between the polymer and mucosal tissue recorded as
a plot of the load on microsphere versus mobile stage distance or deformation. The plot
of output of the instrument is unique in that it displays both the compressive and the
tensile portions of the experiment. By using the CAHN soft ware system, three essential
mucoadhesive  parameters  can  be  analyzed.  These  include  the  fracture  strength,
deformation to failure and work of adhesion. 
 Fracture strength: it is the maximum force per unit surface area required to break the
adhesive bond.
Deformation to failure: it is the distance required to move the stage before complete
separation occurs. This parameter is dependent on the material stiffness and the intensity
of strength of adhesion.
 Work of adhesion: It is a function of both the fracture strength and the deformation to
failure. It tends to be the strongest indicator of the bioadhesive potential. This technique
allows the measurement of mucoadhesive properties of a candidate material in the exact
geometry of the proposed microsphere delivery device and the use of a physiological
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tissue  chamber  mimics  the  in  vivo  conditions.  From a  single  tensile  experiment,  11
mucoadhesive parameters can be analyzed out of which 3 are direct predictors of the
bioadhesive  potential.  The  CAHN instrument,  although a  powerful  tool  has  inherent
limitations in its measurement technique, makes it better suited for large microspheres
(with a diameter of more than 300µm) adhered to tissue in vitro. Therefore, many new
techniques have been developed to provide quantitative information of mucoadhesive
interactions of the smaller microspheres.
 (b) Novel Electromagnetic Force Transducer (EMFT)
The EMFT is a remote sensing instrument that uses a calibrated electromagnetic
to  detach a  magnetic  loaded  polymer  microsphere  from a tissue  sample26. It  has  the
unique ability to record remotely and simultaneously the tensile force information as
well  as  high  magnification  video  images  of  mucoadhesive  interactions  at  near
physiological conditions. The EMFT measures tissue adhesive forces by monitoring the
magnetic  force  required  to  exactly  oppose  the  mucoadhesive  force.  To  test  a
microsphere,  it  must first  be attached to the sample of tissue; magnetic force is then
generated by an electromagnet mounted on the microscope vertically above the tissue
chamber.  After  the  computer  has  calculated  the  position  of  microsphere,  the  tissue
chamber  is  slowly  moved  down,  away  from  the  magnet  tip.  As  the  tissue  slowly
descends away from the magnet, the video analysis continuously calculates the position
of microsphere until the latter is completely pulled free of the tissue. The computer can
display the results either as raw data or convert it to a force versus displacement graph.
The primary advantage of the EMFT is that no physical attachment is required between
the force transducer and the microsphere.  This makes it  possible to perform accurate
mucoadhesive  measurements  on the  small  microspheres,  which  have  been  implanted
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in vivo and then excised (along with the host tissue) for measurement. This technique can
also be used to evaluate the mucoadhesion of polymers to specific cell types and hence
can be used to develop mucoadhesive drug delivery system (MDDS) to target- specific
tissues27.
(c) Shear Stress Measurement 
The shear  stress  measures  the force  that  causes  a  mucoadhesive to slide with
respect to the mucus layer in a direction parallel to their plane of contact28. Adhesion
tests based on the shear stress measurement involve two glass slides coated with polymer
and a film of mucus. Mucus forms a thin film between the two polymer coated slides,
and the test measures the force required to separate the two surfaces. Mikos and Peppas29
designed the in vitro method of flow chamber. The flow chamber made of Plexiglas is
surrounded  by  a  water  jacket  to  maintain  a  constant  temperature.  A  polymeric
microsphere placed on the surface of a layer of natural mucus is placed in a chamber. A
simulated  physiologic  flow of  fluid  is  introduced  in  the  chamber  and  movement  of
microsphere is monitored using video equipment attached to a goniometry, which also
monitors the static and dynamic behavior of the micro particles.
(d) Adhesion Number 
Adhesion number for mucoadhesive microspheres is determined as the ratio of
the number of particles attached to the substrate to the total number of applied particles,
expressed  as  a  percentage.  The  adhesion  strength  increases  with  an  increase  in  the
adhesion number.
(e) Falling Liquid Film Method
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It is a simple, quantitative in situ method, wherein an excised intestinal segment
cut lengthwise, is spread on a plastic flute and positioned at an incline. The suspension of
microsphere is allowed to flow down the intestinal strip. Particle concentrations entering
the segment from the dilute suspension reservoir and leaving the intestinal segment can
be determined with the help of coulter counter to quantify the steady state fraction of
particles adhered to the intestinal mucosa. The percent of particles retained on the tissue
is calculated as an index of mucoadhesion30.
(f) Everted Sac Technique 
The  everted  intestinal  sac  technique  is  a  passive  test  for  mucoadhesion  and
involves  polymeric  microspheres  and  a  section  of  the  everted  intestinal  tissue.  It  is
performed using a segment of intestinal tissue excised from the rat, everted, legated at
the ends and filled with saline.  It  is  then introduced into a tube containing a known
amount of the microspheres and saline, and agitated while incubating for 30 min. Sac is
then removed, microspheres are washed and lyophilized, and the percentage of binding
to the sac is calculated from difference in the weight of the residual spheres from the
original weight of the microspheres31. The advantage of the technique is that no external
force applied to the microspheres  being tested;  microspheres  are  freely suspended in
buffer solution and made to come in contact with the everted intestinal tissue randomly.
The CAHN technique and the everted intestinal sac technique, both predict the strength
of mucoadhesion in a very similar manner. Santos et al established a correlation between
the two in vitro mucoadhesion assay methods, which thereby allows one to confidentially
utilize a single mucoadhesion assay to scan a variety of mucoadhesive polymers.
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INVIVO TECHNIQUES
(g) Measurement of the Residence
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Time measurements of the residence time of mucoadhesive at the application site
provide quantitative information on their mucoadhesive properties. The GI transit times
of  many  mucoadhesive  preparations  have  been  examined  using  radioisotopes  and
fluorescent labeling techniques.
(h) GI Transit Using Radio-Opaque Microspheres
It is a simple procedure involving the use of radio-opaque markers,  e.g.  barium
sulfate,  encapsulated  in  mucoadhesive  polymers  to  determine  the  effects  of
mucoadhesive polymers on GI transit time. Feces collection (using automated feces
Collection machine) and X-ray inspection provide a non-invasive method of monitoring
total  GI residence time without affecting normal GI motility.  Mucoadhesives  labeled
with  Cr-51,  Tc-99m,  In-113m,  or  I-123  have  been  used  to  study the  transit  of  the
microspheres in the GI tract. 
(i) Gamma Scintigraphy Technique 
Distribution and retention time of the mucoadhesive intravaginal  Microspheres
can  be  studied  using  the  gamma  scintigraphy  technique.  A  study  has  reported  the
intensity  and  distribution  of  radioactivity  in  the  genital  tract  after  administration  of
technetium  labeled  hyaluronic  acid  esters  microspheres.  Dimensions  of  the  vaginal
cavity of the sheep can be outlined and imaged using labeled gellan gum and the data
collected  is  subsequently  used  to  compare  the  distribution  of  radio  labeled  HYAFF
formulations.  The  retention  of  mucoadhesive-radio  labeled  micro  spheres  based  on
HYAFF polymer was found32 to be more for the dry powder formulation than for the
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pessary  formulation  after  12  hours  of  administration  to  vaginal  epithelium.  The
combination of sheep model and gamma scintigraphy method has been proved to be an
extremely  useful  tool  for  evaluating  the  distribution,  spreading  and  clearance  of
vaginally administered mucoadhesive drug delivery system, including microbicides.
2.3.4.2    Surface Characterization of the Mucoadhesive Microspheres
Surface morphology of microspheres and the morphological  changes produced
through  polymer  degradation  can  be  investigated  and  documented  using  scanning
electron  microscopy (SEM),  electron  microscopy and scanning tunneling microscopy
(STM). To assess the effect of surface morphology on the mucoadhesive properties, the
microsphere samples are lyophilized and analyzed under SEM at 150 µm and 1000 µm.
The smooth texture of the microsphere surface leads to weak mucoadhesive properties,
while the coarser  surface texture improves the adhesion through stronger  mechanical
interactions41.  The  morphological  surfaces  changes  occurring  due  to  the  hydrolytic
degradation of the polymers,  e.g.:  polyanhydrides  can be studied after  incubating the
microspheres in the PBS buffer for different intervals of time.
Table 2
SUMMARY OF RESEARCH WORK ON MUCOADHESIVE MICROSPHERES
AND MICROCAPSULES
DRUG POLYMER ROUTE PURPOSE/RESULT
Furosemide AD-MMS (PGEFs) GI
Increased bioavailability
Higher AUC
Riboflavin AD-MMS (PGEFs) GI —
Amoxicillin AD-MMS (PGEFs) GI
Greater anti H. pylori
activity
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Delapril Hcl
(prodrug) 33
PGEFs GI
MRT of drug is increased
plasma concentrations of
the active metabolite are
sustained
Amoxicillin34
Polycarbopol/Carbopol
934 /Ion exchange resin
GI
Greater anti H. pylori
activity
Cephradine35 Chitosan/ Ethyl cellulose GI
Prolonged the intestinal
absorption
Indomethacin36 Sodium Alginate
CMC/MC/Carbopol/HPMC
Oral Slow release rates
Glipizide37 Sodium Alginate
CMC/MC/Carbopol/HPMC
Oral Slow release rates
AD-MMS :  Adhesive Micro matrix System
AUC :  Area under Curve
MRT :  Mean Residence Time
2.4 STATISTICAL OPTIMIZATION TECHNIQUE
23 Factorial Design 38
The main objective of a factorial experiment is to be able to determine (or) at
least the estimate the factor effects, which indicates how each factor affects the process
output.  Factor  effects  need  to  be  understood  so  that  the  factors  can  be  adjusted  to
optimize the process output. The effect of each factor on the output can be due to it alone
(main effect of the factor), (or) a result of the interaction between the factor and one (or)
more of the other  factor  (interactive  effects).  When assessing factor  effects  (whether
main (or)  interactive  effects),  one  needs  to  consider  not  only the magnitudes  of  the
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effects, but their directions as well. The directions of an effect determine the direction in
which factors need to be adjusted in a process in order to optimize the process output.
In factorial designs, the main effects are referred to using single uppercase letters,
(e.g.) the main effects of factor A, B&C is referred to simply as A, B&C respectively. An
interactive effect, on the other hand, is referred to by a group of letters denoting which
factors are interacting to produce the effect,  (e.g.,)  the interactive effect  produced by
factors A, B&C is referred to as ABC. 
The magnitude and polarity (or direction) of the numerical values of main and
interactive  effects  indicates  how this  affects  influences  the  process  output.  A higher
absolute value for an effect means that the factor responsible for it affects the out put
significantly. A negative value means that increasing level(s) of the factor (s) responsible
for that effect will decrease the output of the process. (Table 2 & 3) 
                                                Design experiments
                                         Table. 3
                                      Levels of Factors
Table 4.
Factor Low level High level
A - +
B - +
C - +
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Two- level-3-factor- full-factorial Experiment design pattern
                                                  
Run Combination
Factors
A B C
1 (1) - - -
2 A + - -
3 B - + -
4 AB + + -
5 C - - +
6 AC + - +
7 BC - + +
8 ABC + + +
3.0 LITERATURE REVIEW
Mucoadhesive microspheres include micro particles and microcapsules (having a
core  of  the  drug)  of  1-1000  µm  in  diameter  and  consisting  either  entirely  of  a
mucoadhesive polymer or having an outer coating of it, respectively8. Microspheres, in
general, have the potential to be used for targeted and controlled release drug delivery;
but coupling of mucoadhesive properties to microspheres has additional advantages, e.g.
efficient absorption and enhanced bioavailability of the drugs due to a high surface to
volume ratio, a much more intimate contact with the mucus layer, specific targeting of
drug to the absorption site achieved by anchoring plant lectins9, bacterial adhesions10 and
antibodies11, etc. on the surface of the microspheres. Mucoadhesive microspheres can be
tailored to adhere to any mucosal tissue including those found in eye, nasal cavity and
urinary and gastrointestinal tract, thus offering the possibilities of localized as well as
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systemic controlled release of drugs. Application of mucoadhesive microspheres to the
mucosal tissues of ocular cavity, gastric and colonic epithelium is used for administration
of drugs for localized action. Prolonged release of drugs and a reduction in frequency of
drug administration to the ocular cavity can highly improve the patient compliance12
Amoxicillin mucoadhesive Microspheres39 were prepared using ethyl  cellulose
(EC) as matrix and carbopol 934P as mucoadhesive polymer for the potential  use of
treating gastric and duodenal ulcers, which were associated with Helicobacter pylori.  In
vitro release  test  was  done  in  pH  1.0  (HCl)  and  in  pH  7.8  phosphate  buffer.  In
conclusion,  the  prolonged  gastrointestinal  residence  time  and  enhanced  amoxicillin
stability  resulting  from  the  mucoadhesive  microspheres  of  amoxicillin  might  make
contribution to Helicobacter pylori clearance.
Mucoadhesive microspheres prepared40 containing either amoxicillin or clarithromycin
by interpolymer complexation of poly acrylic acid  (PAA) with poly vinyl pyrrolidone
(PVP) and solvent diffusion method.  The loading efficiency of clarithromycin in the
complex microspheres was higher than that of amoxicillin due to the stronger interaction
of clarithromycin with the PAA. The microspheres had a spherical shape with a smooth
surface and the inside of the microspheres was completely filled. The release mechanism
of amoxicillin was mainly by a diffusion process and that of clarithromycin was via a
dissolution process.
Venlafaxine  extended-release  capsules41 were   studied  in  panic  disorder.
Venlafaxine ER was not associated with a greater proportion of patients free from full-
symptom panic attacks at the final on-therapy evaluation, but was associated with lower
mean panic attack frequency and a higher proportion free from limited-symptom panic
attacks, higher response and remission rates, and improvements in anticipatory anxiety,
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fear  and  avoidance.  Adverse  events  were  comparable  with  those  of  the  drug  in
depression  and  anxiety.  Sustained  release  Venlafzxine  HCl wax matrix  tablets84 was
prepared and optimized; the effect of Bees wax and Carnauba wax on the drug release
profile was investigated. Both waxes retarded release but Bees wax showed significant
influence. 
Indion 244-Venlafaxine HCl complexes  83  were prepared the optimum pH,drug
loading efficiency were determined which changed crystalline character of the drug to
amorphous form and sustained formulation. Method of manufacturing sustained release
micro beads containing venlafaxine HCl42 were studied. A sustained release venlafaxine
composition  that  includes  of  a  non-agglomerated,  uniformly  shaped  and  sized  micro
beads of inert core particles having a first coating layer  in a concentration of at least
about 5% to about 70% by weight of the composition, the binder is present in an amount
of at least 35% by weight of the active agent, or in a further layer located upon or below
the first coating layer, or as an alternating layer between plural first layers. The prepared
sustained release microbeads containing Venlafaxine HCl used for once a management of
major anxiety disorders.
Nifidepine microsphere 43 were prepared using Eudragit RL as a matrix material,
by  emulsion  solvent  evaporation  method  using  methylene  chloride  as  solvent;  The
solution was emulsified in 0.8% polyvinyl alcohol at room temperature. Thus prepared
microspheres  were  evaluated  for  their  drug  content,  particle  size,  distribution,  bulk
density,  in  vitro  dissolution,  in  vivo  bioavailability  using  cross  over  design  and  the
stability  study  on  microsphere  performed  at  4oC,  25oC and  50Oc.  Chlorpromazine
hydrochloride  (CPH)  microspheres44 were  prepared  using  ethyl  cellulose  (EC)  as
retardant, by using solvent evaporation and non-solvent addition. In both the methods,
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three different drug to polymer concentration (1:1, 1:1.5, and 1:2) were utilized for the
preparation. Solvent evaporation method yielded microsphere of poly-dispersed sizes and
un-uniform rough surface. Microspheres obtained from the non-solvent addition method
were uniform, smooth and these were subjected for evolution. Tableting microcapsule
consisting  of  ethyl  cellulose  shells  or  walls  containing  sodium  Phenobarbital  in  the
cores45 investigated. Dissolution from the capsules was found to depend on the core-wall
ratio and the size of the dried microcapsules aggregates in the tablet. With a higher core-
to-wall ratio the microcapsules have thinner walls so that the dissolution medium can
enter the capsules more readily and the core solution can easily pass through the walls.
The larger  the microcapsules  the greater  the breakdown of  the  aggregates,  providing
additional surface for dissolution. Thus, both core-to-wall ratio and size of microcapsule
aggregates increase the dissolution rate of the tableted microcapsules. 
Mucoadhesive  microspheres46, were  developed  that  can  be  utilized  for  the
controlled release of triclosan in oral-care formulations, specifically dental paste. Using a
double–emulsion  solvent  evaporation  technique,  triclosan  was  incorporated  into
microspheres. Carbopol 934P, polycarbophil or chitosan and the profiles for its releases
were established under simulated ‘in use’ conditions. The work has demonstrated that
these polymeric microspheres, particularly those of chitosan, are promising candidates for
the  sustained  release  of  triclosan  in  the  oral  cavity.  Metoclopramide  microspheres  47
prepared containing a mucoadhesive polymer chitosan and investigated with a view to
develop  mucoadhesive  microspheres.   The  chitosan  microspheres  were  prepared  by
simple emulsification phase separation technique using glutaraldehyde as a cross linking
agent. Results of preliminary trials indicate that volume of cross-linking agent, time for
cross-linking  and  speed  of  rotation  affected  characteristics  of  microspheres.
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Metoclopramide release from these mucoadhesive microspheres was slow, extended and
depended  on  the  polymer  to  drug  ratio.  Drug  release  was  diffusion  controlled  and
followed  non-Fickian  diffusion.  Indomethacin  microcapsules  with  a  coat48, were
formulated consisting  of  alginate  and  a  mucoadhesive  polymer  such  as  sodium
carboxymethylcellulose,  methylcellulose,  carbopol  and  hydroxypropylmethylcellulose
were prepared by an emulsification–ionic gelation process. The resulting microcapsules
were discrete, large, and spherical and free flowing. Microencapsulation efficiency was
41-70% and relatively high with alginate-sodium carboxymethylcellulose.  Release from
some microcapsules  fulfilled the official  (USP 23) drug release  test-2 requirement  of
indomethaoin extended release capsules.
Metoprolol tartarate biodegradable microspheres50  were prepared using chitosan
by the phase separation emulsification technique.  Microspheres of 1:0.5, 1:1 and 1:2
drugs to carrier ratios were prepared and thermally cross-linked. Drug to  carrier ratio 1:1
showed maximum percentage yield and highest drug entrapment.  The size range of the
microspheres  varies  from 3.5 to 31.5  µm.  UV and DSC studies were carried out to
confirm the presence and stability of the drug in the microspheres.  Short-term stability
studies  were  carried  out  to  confirm  the  presence  and  stability  of  the  drug  in  the
microspheres. Mucoadhesive properties and gastrointestinal transit of microspheres made
of  oppositely  charged  dextran  derivatives  and  cellulose  acetate  butyrate  (CAB) 50.,
evaluated.   The microspheres were prepared by emulsion solvent evaporation method.
Microspheres with a diameter of 425-710 µm were examined for in vitro mucoadhesion
by the everted sac method.  The results indicated that the percentage of adherence to the
rat small intestine was affected by the amount of dextran derivatives in the microspheres.
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Diclofenac sodium by using sodium microspheres51,  were prepared alginate as a
polymer  and calcium chloride  as  a  cross  linking agent.   In  this  investigation,  3  full
factorial design was used to investigate the joint influence of three variables: the stirring
speed (x1), concentration of CaCl2 (X2), and percent of heavy liquid paraffin in a blend of
heavy and light liquid paraffin in the dispersion medium (X3)  on the time required for
80% drug  dissolution  (t80).   The  result  of  multiple  linear  regression  analysis  and  F-
statistics revealed that, for obtaining controlled drug release, the microsphere should be
prepared  using  relatively  lower  stirring  speed,  higher  interactions  were  found  to  be
statistically significant in nature.  Nitrofurantoin microspheres52 were prepered by using
three polymeric materials viz. Sodium alginate, ethyl cellulose and eudragit RS100 and
reported  that  the  microcapsules  prepared  with  sodium  alginate  and  ethyl  cellulose
demonstrated slower release than those prepared with eudragit RS100.
Ethyl  cellulose  microcapsules53  was  studied  for  its  permeability  which  was
prepared  by  three  coacervation  methods  of  aspirin  metronidazole,  paracetamol,
tolbutamide;  and  they  reported  that  with  all  the  medicaments,  high  permeability,
constants  were  observed  in  case  of  microcapsules  prepared  by  thermal  included
coacervation and less permeability when prepared by coacervation by the addition of
non-solvents. Theophylline microspheres,54  was prepared by ionotropic gelation method
and  investigated  the  influence  of  variables  such  as  stirring  speed,  concentration  of
calcium chloride,  and composition of dispersion medium on the characteristics of the
microsphere. The microspheres were evaluated during  in vivo studies in dogs and the
pharmacokinetics  parameters  were  estimated  by  performing  non-linear  regression
analysis.  The  Wagner-Nelson  method  was  adopted  to  compute  the  percentage  drug
absorbed.  A good correlation was observed between the in vitro and in vivo results.
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Mucoadhesive properties of chitosan microspheres55 were prepared by different
methods were evaluated by studying the interaction between mucin and microspheres in
aqueous  solution.  The  interaction  was  determined  by  the  measurement  of  mucin
adsorbed on the microspheres. A strong interaction between chitosan microspheres and
mucin was detected. The intensity of the interaction was dependent upon the method of
preparation of chitosan microspheres  and the amount of mucin added.  The extent of
mucus adsorption was proportional to the absolute values of the positive zeta potential of
chitosan microspheres. The zeta potential in turn was found to be dependent upon the
method of preparation of microspheres. The adsorption of type III mucin (1% sialic acid
content) was interpreted using Freundlich or Langmuir adsorption isotherms. The values
of  r2 were greater for Langmuir isotherm as compared with Freundlich isotherm. The
adsorption of a suspension of chitosan microspheres in the rat small intestine indicated
that chitosan microspheres prepared by tripolyphosphate cross-linking and emulsification
ionotropic  gelation  can  be  used  as  an  excellent  mucoadhesive  delivery  system.  The
microspheres  prepared  by  glutaraldehyde  and  thermal  cross-linking  showed  good
stability  in  HCl  as  compared  with  microspheres  prepared  by  tripolyphosphate  and
emulsification ionotropic gelation.
The  chitosan  microspheres56, were  prepared  by  a  membrane  emulsification
method  with  variations  of  the  N2 gas  pressure  and  the  chitosan  concentration.  The
pressure of N2 gas was varied within the range from0.2 X 105 to 0.8 X 105 Pa at chitosan
concentration 1.5 % wt/wt. In addition, the concentration of chitosan was varied between
0.5 ~ 2.0 % wt/wt at 0.4 X 105 Pa of N2 gas pressure. Using this method, it is possible to
prepare stable emulsions with a very narrow droplet size distribution in comparison with
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conventional methods. The average size of the microspheres was dependent on the N2
gas pressure  and the concentration that  is  it  was increased with the pressure and the
concentration.  The  modeling  of  the  size  for  the  microspheres  according  to  the
concentration was carried out using Macleod’s relation and Parkins & Brown equation.
The former shows the relationship between density and surface tension and the latter
demonstrates the correlation between the volume of the microspheres and the interfacial
tension. The modeling results  were  in good agreement with the experimental  data to
predict  the  microspheres  size  with  the  variation  of  concentration.  Mucoadhesive
microspheres were  developed that can be utilized for the controlled release of triclosan57
in oral-care formulations,  specifically dental  pastes.  Using a double-emulsion solvent
evaporation technique, triclosan was incorporated into microspheres that were prepared
from Gantreze MS-955, Carbopol 974P, polycarbophil or chitosan and the profiles for its
release  were  established  under  simulated  ‘in  use’  conditions.  Triclosan  was  rapidly
released  into  a  sodium  lauryl  sulphate-containing  buffer  from  all  but  the  chitosan
microspheres. The release of triclosan from microspheres suspended in a non-aqueous
paste, was found to be sustained over considerable time-periods, which were influenced
strongly by the nature of the polymeric carrier. For microspheres that were fabricated
from  Gantrez,  Carbopol  or  polycarbophil,  the  release  appeared  to  obey  zero-order
kinetics whereas in the case of chitosan-derived vehicles, the release profile fitted the
Baker  and  Lonsdale  model.  The  work  has  demonstrated  that  these  polymeric
microspheres, particularly those of chitosan, are promising candidates for the sustained
release of triclosan in the oral cavity.
The influence  of three  solvents for the polymer  (chloroform,  dichloromethane
and ethyl acetate) 58  employed in the preparation on the drug release microcapsules were
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prepared by an emulsion solvent evaporation method was studied. All the three solvents
gave discrete, large sized, free flowing spherical microcapsules. The microcapsules were
valuated for  size analysis,  drug content,  microencapsulation efficient,  wall  thickness,
drug release characteristics, influence of solvent employed on diclofenac sodium release
from microcapsules, surface characteristics. Diclofenac release from the microcapsules
and the solvent employed in their preparation. Among the solvents employed chloroform
was  found  to  be  more  suitable  for  slow  release  of  diclofenac  from  ethyl  cellulose
microcapsules.
Mucoadhesive  microspheres  59 were  formulated  containing  the  mucoadhesive
polymer chitosan hydrochloride, with matrix polymer Eudragit RS-100, pipemidic acid
as a model drug and agglomeration preventing agent magnesium stearate by the solvent
evaporation method. The amount of magnesium stearate was varied and the following
methods  were  used  for  microsphere  evaluation:  sieve  analysis,  drug  content  and
dissolution determination, scanning electron microscopy, X-ray diffractometry, DSC and
FTIR  spectroscopy.  The  results  showed  that  average  particle  size  decreased  with
increasing  amount  of  magnesium  stearate  used  for  microsphere  preparation.  This  is
probably  a  consequence  of  stabilization  of  the  emulsion  droplets  with  magnesium
stearate.  Higher  pipemidic  acid  content  in  the  microspheres  was  observed  in  larger
particle size fractions and when higher amounts of magnesium stearate were used. It was
also found that these two parameters significantly influenced the dissolution rate. The
important reason for the differences in drug content in microspheres of different particle
sizes is the diffusion of pipemidic acid from the acetone droplets in liquid paraffin during
the preparation procedure. The physical state of pipemidic acid changed from crystalline
to  mostly  amorphous  with  its  incorporation  in  microspheres,  as  shown  by  X-ray
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diffractometry and differential scanning calorimetry. No differences were observed in the
physical state of pipemidic acid and in microsphere shape and surface between different
size fractions of microspheres, prepared with different amounts of magnesium stearate.
Additionally,  no  correlation  between  the  physical  state  of  the  drug  in  different
microspheres and their biopharmaceutical properties was found.
The Spherical  matrices and microcapsules of Nimesulide60  were formulated by
using  ethyl  cellulose  (E.C)  as  coating  material,  by  reported  methods  spherical
agglomeration technique indomethacin and emulsion solvent evaporation technique for
theophylline and studied the in-vitro drug release  pattern from both the matrices  and
microcapsules of different sizes (20/40 and 40/60) and different coating thickness (10%,
20% and 25%) for about eight hours. It was found that the drug release from matrices
was slow compared to that from microcapsules.
Modified release microspheres of Ibuprofen61 were prepared by emulsion solvent
diffusion method. The technique was optimized for the following processing variables
the absence / presence of baffles in the reaction vessel, agitation rate and drying time.
Thereafter,  the  influence  of  various  formulation  factors  on  the  microencopsulotion
efficiency.  In  vitro  drug  release  and  micromeritic  properties  were  examined.  The
variables included the methacrylic polymer, Eudragit RS100, ibuprofen content and the
volume of ethanol used during microencapsulation. The results obtained were interpreted
on a triangular phase diagram to map the region of microencapsulation, as well as those
formulations that yielded suitable modified release ibuprofen microspheres.
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The  forgiving  literature  review  indicates  that  Venlafaxine  HCl  has  been
investigated  as  extended  release  capsules41,  sustained  release  was  matrix  tablets84,
complex with Indion 24483, and sustained release microbeades42. However, to the best of
our knowledge; the mucoadhesive-microspheres of Venlafaxine HCl for targeted drug
delivery has not been studied, and hence the present investigation was directed towards
developing  the  mucoadhesive  microspheres  of  Venlafaxine  HCl  with  greater
bioavailability and enhanced loading efficiency.  
4.0 AIM AND OBJECTIVE OF THE WORK
Venlafaxine HCl is  a  new generation  anti  depressant  serotonine/noradrenaline
reuptake  inhibitor  drug  showing  effective  anti-depressant  properties.  It  has  a  short
bioavailability 12.6% and biological half-life of 5 hours. So, frequent administration is
necessary  to  maintain  its  therapeutic  concentration.  This  necessitates  multiple  daily
dosing for maintenance of its plasma concentration of the drug within the therapeutic
index;  hence  there  is  an  impetus  for  developing  sustained  release  dosage  form that
maintains improved bioavailability and therapeutic plasma drug concentration for long
period compared to conventional dosage forms.
The objective of the present study is to design a prolonged release dosage form to
be used for targeted and controlled release drug delivery, preparation of mucoadhesive
microspheres containing venlafaxine HCl,  helps in releasing small quantities of drug,
advantage for treating of depressive disorders. 
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Slowly dissolving polymers for sustaining the release may be suitable for long-
term  therapy  in  controlled  alleviation  of  clinical  manifestation.  Ethyl  cellulose  and
Eudragit RS100 provide a potentially useful means of delivering drugs because they are
stable,  both  physically  and  chemically  amenable  to  preparation  in  large  batches.
However  the  present  work  is  aimed to  design  and  evaluate  the  mucoadhesive
microspheres of Venlafaxine HCl
In this present work the mucoadhesive microspheres  of venlafaxine HCl were
prepared employing 23factorial design by using Ethyl cellulose (EC) along with Eudragit
RS100 and Hydroxy Propyl Methylcellulose (HPMC K4M). In this experimental model,
our goal is to determine how the t80% of drug release and mucoadhesive characters can be
affected by adjusting three parameters: concentration of polymers EC, Eudragit RS100 &
HPMC K4M of the mucoadhesive microspheres. For each of these parameters, the levels
will define for use in this 2-level experiment. In formulations, the low and high levels of
EC, EUDRAGIT RS100 and HPMC K4M were 750 mg and 1000 mg, 100 mg, 200 mg
and  200 mg, 300 mg respectively.
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5.0 PLAN OF WORK
Present work was carried out to design and evaluate the mucoadhesive microspheres of 
Venlafaxine HCl.
1. Preformulation studies 
a) Selection of Mucoadhesive Polymers
b) Compatibility study
i. Fourier Transform Infrared Spectroscopy (FTIR)
ii. Differential Scanning Calorimetry (DSC)
2. Preparation of standard curve of Venlafaxine HCl
a) Standard curved for Venlafaxine HCl in 0.1 N HCl(pH 1.2)
b) Standard curved for Venlafaxine HCl  in phosphate buffer pH 6.8
3. Formulation of mucoadhesive microspheres of Venlafaxine HCl
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 Using a combination of Ethyl Cellulose, and Eudragit RS100 as a rate-
controlling polymer along with mucoadhesive polymer HPMC K4M employing 
23factorial design.
4. Evaluation of the prepared mucoadhesive microspheres of venlafaxine 
HCl
a) Percentage yield. 
b) Particle size distribution by microscopic method.
c) Angle of repose.
d) Bulk density.
e) Drug content.
f) Encapsulation efficiency.
g) Shape and Surface characterization of the prepared micro spheres (SEM).
h) In vivo wash–off test
i) In vitro dissolution studies. 
j) Interpretation of drug release mechanism by kinetic models
k) Optimization of the formulation using  f2 similarity factor  
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6.0 PROFILES
6.1 DRUG PROFILE 62, 80
Name of the drug : Venlafaxine HCl
Chemical Name : 1-[2-dimethyl amine-1-(4- methoxy phenyl)   
                                                                        Ethyl]cyclohexane-1-ol
Structure             :
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Molecular Formula             : C17H27NO2 HCl          
Molecular Weight             : 313.9             
 Melting point                                    :           216  
Category             :           Oral antidepressant
Description             :  It is crystalline white powder,
Solubility                                     :   Freely soluble in water, methanol,         
                                                                           Chloroform &sparingly soluble in acetone
Dose                                        :                         37.5 -225mg per day after meals
Clinical pharmacology
Pharmacodynamics                            :                          
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The mechanism of the antidepressant action of venlafaxine in human is believed
to be associated withits potentiation of neurotransmitter activity in the CNS. Preclinical
studieshave  shown  that  venlafaxine  and  its  active  metabolite,  O-  desmethyl
Venlafaxine(ODV),are  potent  inhibitors  of  neuronal  serotonin  and  nor  epinephrine
reuptake  and  weak  inhibitors  of  dopamine reuptake.  Venlafaxine and  ODV have  no
significant  affinity  for  muscarinic  cholinergic,  H1  histaminergic,  or  α1-adrenergic
receptorsin  vitro.  Pharmacological  activity  at  these  receptors  is  hypothesized  to  be
associated with various anticholinergic,  sedative, and cardiovascular  effects seen with
other  psychotropic  drugs.  Venlafaxine  and  ODV do  not  posses monoamine  oxidase
(MAO) inhibitory activity.
Pharmacokinetics
Steady state concentration of venlafaxine and ODV in plasma is attained within 3
days of oral multiple dose therapy .Venlafaxine and ODV exhibited linear kinetics over
the  dose  range  of  75  to  225mg/day.  mean±  SD  steady  state  plasma  clearance  of
venlafaxine  and  ODV is  1.3± 0.6and0.4±0.2L/hkg  ,respectively and  (apparent)steady
state volume of distribution is  7.5±3.7 and 5.7±1.8L/kg,respectively .Venlafaxine and
ODV are minimally bound at therapeutic concentrations to plasma proteins (27% and
30%,respectively)
Mechanism of action 
Venlaflaxine HCl is  a  bicyclic  antidepressant,  and is  usually categorized as  a
serotoninor epinephrine reuptake inhibitor, but it has been referred to as a serotonium-
nor  epinephrine  –dopamine  reuptake  inhibitor.  It  works  by  blocking  the  transporter
“reuptake”  proteins  for  key  neurotransmitters  affecting  mood,  thereby  leaving  more
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active synapse.At low dosage, Venlafaxine blocks serotonium reuptake alone, similarly
to a selective serotonium reuptake inhibitor (SSRI).  At medium dosages,  Venlafaxine
blocks  the  reuptake  of  nor  epinephrine  as  well  as  serotonium.  At  dosages  above
300mg/day,it blocks dopamine reuptake in addition to serotonium and nor epinephrine.
Absorption
Venlafaxine  is  well  absorbed  and  extensively  metabolized  in  the  liver.  O-
desmethylvenlafaxine (ODV) is the only major active metabolite. On the basis of mass
balance  studies,  at  least  92% of a  single  oral  dose  of  Venlafaxine  is  absorbed.  The
absolute bioavailability of Venlafaxine is about 45%.
Metabolism and Excretion
Following  the  absorption,  Venlafaxine  undergoes  the  extensive  presystemic
metabolism in the liver, primarily to ODV ,But also to N-desmethylvenlafaxine, N,O-
desmethylvenlafaxine  and  other  minor  metabolites.  In  vitro  studies  indicate  that
formation of ODV is catalyzed by CYP2D6;this has been confirmed in a clinical study
showing the patients with low CYP2D6 levels had increased levels of Venlafaxine and
reduced  levels  of  ODV,  compared  to  people  with  normal  CYP2D6.The  differences
between  CYP2D6 poor  and  extensive  metabolizers  are  not  expected  to  be  clinically
important  because  the  sum  of  venlafaxine  and  ODV  is  similar  in  two  groups  and
venlafaxine and ODV are pharmacologically approximately equiactive and equipotent.
Dosing
The dose  of  Venlafaxine  will  be  different  for  different  patients.  Follow your
doctor’s orders or the directions for on the label. The following information includes
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only the average doses of Venlafaxine HCl. The number of capsules or tables that you
take depends on the strength of the medicine. Also, the number of doses you take each
day,  the time allowed between doses,  and the length  of  time you  take  the medicine
depend on your special needs.
Therapeutic uses
For mental depression:
For oral extended-release capsule dosage form:
Adults-At first, 75 milligrams(mg) a day, taken in one dose in the morning or evening.
However the dose is usually not more than 225mg a day.
Children’s-Use and dosage must be determined by your doctor.
For oral tablet dosage form.
Adults, at first, a total of 75mg per day, taken in the smaller doses two or three times
during the day. However the dose is usually not more than 375 mg a day.
Children up to 18yrs of age – Use and dose must be determined by your doctor.
For anxiety:
For oral extended-release capsule dosage form:
Adults—At first, 75mg a day taken in one dose in the morning or evening. However the
dose is usually not more than 225mg per day.
Children—Use and dose must be determined by your doctor. Take the missed dose as
soon as you remember.  However if it  is almost time for your next regular scheduled
dose, skip the missed dose and take only the next one as directed. Do not take double
dose for this medication.
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Missed dose
Take the missed dose as soon as you remember. However if it is almost time for
your next regularly scheduled dose, skip the missed dose and take only the next one as
directed. Do not take the double dose for this medication.
Side effect:
Along with  its  needed  effects,  a  medicine  may cause  some unwanted  effects
although not all of these side effects may occur.
More Common: High Blood pressure.
Other  side effects  may occur  that  usually  do not need  medical  attention.  These  side
effects  may  go  away  during  treatment  as  your  body  adjusts  to  the  medicine.  More
common Abnormaldreams; anxietyornervousness; chills; constipation;diarrhea;dizziness;
drowsiness; dryness of mouth; heartburn; increased sweating ;loss of appetite; nausea;
stuffy;  burning; or prickly sensation; trembling; trouble in sleeping; unusual tiredness;
weakness; vomiting; weight loss.
Less common: Change in sense of taste muscle tension.
Rare:  Convulsions;  itching  or  skin  rash;  lightheadness  or  fainting,  especially  when
getting  up  suddenly  from  sitting  or  lying  position;  lock  jaw;  menstrual  changes;
problems in urinating or in urinating or in holding urine; swelling; talking ,feelings and
acting with excitement and activity you cannot control trouble in breathing.
After you stop using this medicine your body may need time to adjust. The length of
time takes depends on the amount of medicine you were using and how long it you used
it. During this period of time check with your doctor if you notice any of the following
side effects:
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Changes  in  dreaming;  dizziness;  dryness;  headache;  increased  sweating;  nausea;
nervousness; trouble in sleeping ; unusual tiredness or weakness.
Storage
• Keep out of reach of children.
• Store away from heat and direct light
• Do not store in the bathroom near the kitchen sink, or in the other damp places.
Heat or moisture may cause the medicine to break down.
• Do not keep outdated medicine or medicine no longer needed .Be sure that any
discarded medicine is out of reach of children.
6.2. EXCIPIENTS PROFILE 
6.2.1 Eudragit (Polymethacrylates) 63
Polymethacrylates  are  synthetic  cationic  and  anionic  polymers  of
dimethylaminoethyl  methacrylates,  methacrylic  acid,  and  methacrylic  acid  esters  in
varying ratio. 
Chemical Name : Poly(ethyl acrylate, methyl methacrylate, 
Trimethylammonioethyl methacrylate chloride) 
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1: 2: 0.1
Structure :
For   Eudragit –RS100
R1 =   CH3, C2H5
Molecular Weight : > 100,000 Daltons
Synonym : Acryl-EZE; Acryl-EZE MP; Kolicoat MAE 30 D; 
Kollicoat MAE 30 DP; polymeric    methacrylates.
Trade Name : Eudragit RS 100
Solubility : Soluble  in  Acetone  and  alcohols,  
Dichloromethane,  Solvent  Ethyl  acetate.
Insoluble in water and Petroleum ether, 
Description : Eudragit  RS  100  are  crystalline,  white  powders
with a 
                                                            slight amine-like odor. 
Density (Bulk) : 0.40 g/cm3
    (Tapped) : 0.424 g/cm3
(True) : 0.816.0.836 g/cm3 
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Viscosity : < 7-100 m Pa s 
Stability and 
Storage Condition : Dry    crystalline   polymer    forms    are    stable
at
temperature  less  than  30°C.  Above  this
temperature,  powders  tend  to  form  clumps,
although  this  does  not  affect  the  quality  of  the
substance and the clumps can readily be broken up.
Dry powders are stable for at least 3 years if stored
in a tightly closed container at less than 30°C.
Safety : Polymethacrylate copolymers are widely used as 
Film coating materials in oral pharmaceutical 
formulations. They are also used in topical 
formulations and are generally regarded as 
nontoxic and nonirritant materials.
Handling Precautions : Eye protection,   gloves,   and   a   dust   mask   or 
Respirator  are  recommended.  Polymethacrylates
should be  handled in well-ventilated environment
and  measures  should  be  taken  to  prevent  dust
formation.
Applications : Polymethacrylates     are     primarily     used      in  
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microencapulation,  oral  capsule  and  tablet
formulations as film-coating,  Enteric coating agent
and for sustained release.
6.3. HYDROXYPROPLY METHYL CELLULOSE 64
           It is mixed alkyl-hydroxy alkyl cellulose ether and may be regarded as regarded as
the propylene glycol ether of methyl cellulose.
Chemical name               :   Cellulose, 2- hydroxypropyl methylether.
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Structure                        
                      
                                              where R is H, CH3, or CH3CH(OH)CH2
Molecular weight            :    10000–1500000 daltons
Synonym                                :      Hypromellose
Trade name                     :    Methocel
Solubility                         :     Methocel soluble in cold water, forming a viscous colloidal
                                               solution; practically insoluble in chloroform, ethanol 95%,
                                               and ether, but soluble in mixtures of ethanol and dichloro
                                               methane,  mixtures of methanol and dichloromethane,and 
                                               mixtures of water and alcohol.  
Description                      :    An odorless and tasteless, white or creamy-white fibrous     
                                               or granular powder.
Density                             :   Bulk      :  0.341 g/cm3 
                                          :     Tapped  :  0.557 g/cm3
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                                           :   True       :  1.326 g/cm3
Specific gravity               :    1.26 g/cm3
Viscosity                          :    HPMC K4M,  4000 mPa s ; (2% (w/v) aqueous solution)
Grade                               :    K4M
pH                                    :   5.5–8.0 for a 1% w/w aqueous solution.
Stability                           :  Very stable in dry conditions. Solutions are stable at pH 3-11
Applications                    :  1)In oral products, hypromellose is primarily used as a tablet
Binder, in film-coating, and as a matrix for use in extended
release tablet formulations.
                                              2) Concentrations between 2% and 5% w/w may be used as
a binder in either wet- or dry-granulation processes. 
                                              3) High-viscosity grades may be used to retard the release of
drugs from a matrix at levels of 10–80% w/w in tablets and
capsules.
                                           
6.4. ETHYL CELLULOSE65
Chemical name               :   Cellulose ethyl ether.
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Structure                         :
                                             
Functional Category      :    Coating agent; flavoring fixative; tablet binder; tablet filler; 
                                               Viscosity - increasing agent.
Solubility                        :    Soluble in chloroform, ethanol (95%), ethyl acetate,    
methanol,  and  toluene.  Practically  insoluble  in  glycerin,
propylene glycol, and water.                                     
Description                    :     Ethylcellulose is a tasteless, free-flowing, white to light tan
colored powder.
Bulk density                   :     0.4 g/cm3
Viscosity                         :    7 to 100 mPa s  for a 5% w/v solutions
Specific gravity              :    1.12–1.15 g/cm3
Stability                          :    Ethylcellulose is a stable, slightly hygroscopic material. It is
                                               chemically resistant to alkalis, both dilute and concentrated,
                                               and to salt solutions, although it is more sensitive to acidic 
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                                               materials than are cellulose esters.
Incompatibility               :    Incompatible with paraffin wax and microcrystalline wax.
Safety                               :    Ethylcellulose is widely used in oral and topical    
                                               Pharmaceutical formulations. It is also used in food   
                                               products.
Application                     :    1)   The main use of ethylcellulose in oral formulations is as
a hydrophobic coating agent for tablets and granules.
2)  Ethylcellulose coatings are used to modify the release
of a drug, to mask an unpleasant taste, or to improve the
stability of a formulation; for example, where granules are
coated with ethylcellulose to inhibit oxidation.
3)  Modified-release  tablet  formulations  may  also  be
produced using ethylcellulose as a matrix former.
6.5 SPAN-80
Synonyms: Sorbitan Monolaurate          
 Empirical Formula: C18H34O6 (Sorbitan Monooleate)
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Molecular Weight: 346
Structural formula:
R1 = R2 = OH, R3 = R  for sorbitan monoesters
where R =  (C11H23)COO for laurate
Functional category: Emulsifying agent; nonionic surfactant; solubilizing agent; 
wetting and dispersing/suspending agent.
 Application in pharmaceutical formulation:
 Span  80  are  widely  used  in  cosmetic,  food  products,  and  pharmaceutical
formulations as lipophilic non-ionic surfactants.
 They are mainly used in pharmaceutical formulations as emulsifying agent in the
preparation of creams, emulsion, and ointments for topical application.
 When  used  alone  span  80  produce  stable  water  –in-oil  emulsion  and  micro
emulsion.
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Description:  Sorbitan esters occur as cream to amber-colored liquids or solid with a
distinctive odor and taste. Span 80 occurs as yellow viscous liquid
.
Typical properties:
Stability and storage condition: 
               Gradual soap formation occurs with strong acid or bases; sorbitan esters are
stable in weak acid or bases. Sorbitan esters should be stored in a well- closed container
in a cool, dry place.
Safety: 
            They are generally regarded as non-toxic and non-irritant materials. However,
there have been occasional reports of hypersensitive skin reaction following the topical
application of  product  containing  sorbitan  esters.  When heated  to  decomposition  the
sorbitan esters emit acrid smoke and irritating fumes.
7.0 METHODOLOGY
7.1 MATERIALS USED
POLYSORBAT
E
Density (g/cm3) HLB
VALUE
Viscosity
Span 80 1.01 8.6 2970-4080
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S.No. MATERIALS SUPPLIED BY
1. Venlafaxine HCl ORCHID Pharma Ltd., Kanchipuram
2. Ethyl Cellulose (30-50 cps) Himedia Laboratories Ltd. Mumbai 
3. Hydroxy Propyl MethylCellulose Orchid Lab, Chennai.
4. Eudragit RS100 Micro Labs, Hosur.
5. Span 80 Loba Chemical. Pvt. Ltd. Mumbai
6. Liquid paraffin (light) Loba Chemical. Pvt. Ltd, Mumbai
7. Acetone   AR Research labs fine chemicals, Mumbai.
8. Concentrated HCl LR Nice Chemicals Pvt. Ltd, Chennai
9.
Potassium dihydrogen 
Phosphate AR
Nice Chemicals Pvt. Ltd, Cochin
10. Sodium Hydroxide  LR Nice Chemicals Pvt. Ltd, Cochin
11. Whatmann filter Paper-No.44 Research labs fine chemicals, Mumbai
12. Petroleum ether Chempure, Chennai
                                          7.2. EQUIPMENTS USED
S.No. EQUIPMENTS SUPPLIED BY
1. Magnetic  Stirrer Elektrocrafts Pvt.Ltd., Mumbai
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2. Microscope Acculab
3. UV/Visible spectrophotometer Double beam
Perkin Elmer  Lambda25 
UV/VIS  Spectrophotometer
4.
Dissolution Test Apparatus- U.S.P. 
Standards
Veego  India pvt Ltd.
5. Single Pan Digital Balance Shimadzu. ELB 300
6. Hot Air Oven Inlab equipments
7. Digital pH meter Hanna Instrument.
8. FTIR Spectrophotometer
Perkin Elmer  Spectrum- RX1  
FTIR - Spectrophotometer
9. Scaning Electron Microscope (SEM) Joel model JSM 6400,Tokyo
10. Differential scanning calorimetry DSC DA 2010 Shimadzu, Japan
7.3. PREFORMULATION STUDIES
Before formulation of drug substances into a dosage form, it is essential that drug and
polymer should be chemically and physically characterized. Preformulation studies give
the information need to define the nature of the drug substance and provide a framework
for the drug combination with pharmaceutical excipients in the fabrication of a dosage
form.
7.3.1. SELECTION OF MUCOADHESIVE MICROSPHERES
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Mucoadhesive polymers are water-soluble and water insoluble polymers, which
are swellable networks,  joined by cross-linking agents.  The polymers  should posse’s
optimal polarity to make sure it is sufficiently wetted by the mucus and optimal fluidity
that permits the mutual adsorption and inter penetration of polymer and mucus to take
place.  An  ideal  polymer  for  a  mucoadhesive  drug  delivery  system  should  have  the
following characteristics. 
1. The polymer and its degradation products should be nontoxic and non absorbance
from the gastrointestinal tract. 
2. It should be a nonirritant to the mucous membranes.
3. It should preferably form a strong non-covalent bond with the mucin epithelium 
cell surfaces.
4. It should adhere quickly to moist tissue and should possess some site specificity.
5. It should allow easy incorporation of the drug and offer no hindrance to its 
release. 
6. The polymer must not decompose on storage or during shelf life of the dosage 
form.  In the present work Eudragit RS100 and Hydroxy propyl methylcellulose 
K4M were chosen. 
7.3.2. COMPATIBILITY STUDIES
One of  the requirements  for  the selection of  suitable excipients  or  carrier  for
pharmaceutical formulation is its compatibility. Therefore in the present work a study
was carried out by using FTIR spectrophotometer and Differential Scanning Calorimeter
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(DSC) to find out if there is any possible chemical interaction between Venlafaxine HCl,
Ethyl Cellulose, Hydroxy Propyl Methyl Cellulose and Eudragit RS100.
Pre formulation studies for drug and carrier interaction 
a) Fourier Transform Infrared Spectrophotometry (FTIR) 66,79
Compatibility  study  of  drug  with  the  excipients  was  determined  by  FTIR
Spectroscopy using  : Perkin Elmer  Spectrum- RX1  FTIR - Spectrophotometer . The
pellets were prepared at high compaction pressure by using KBr and the ratio of sample
to KBr is 1:100. The pellets thus prepare were examined and the spectra of drug and
other ingredients in the formulations were compared with that of the original spectra. 
b) Differential scanning colorimeter   (DSC)67
         Differential  scanning  calorimeter  is  used  to  measure  the  specific  heat  and
enthalpies of transition. When a sample undergoes a thermal transition, the power to the
heater is adjusted to maintain the temperature, and a signed proportional to the power
difference is plotted on the second axis of the recorder is known as thermogram. The
area under the resulting curve is direct measure of the heat of transition. Thermograms
were obtained by using a differential scanning colorimeter at a heating rate  10ºC /min
over  a  temperature  range  of  30to  300°C. The sample  was  hermetically  sealed  in  an
aluminum crucible. Nitrogen gas was purged at the rate of 40 ml/min. For maintaining
inert atmospheres.
7.4  CONSTRUCTION OF STANDARD CURVE FOR VENLAFAXINE HCI
Venlafaxine HCl can be estimated spectrophotometrically at 224.0 nm as it obeys
Beer-Lambert’s law.
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Preparation of 0.1 N HCl 
Dilute 8.5 ml of concentrated hydrochloric acid with water to produce 1000 ml.
Preparation of standard drug solution
Stock Solution 
100 mg of Venlafaxine HCl was dissolved in100 ml of 0.1N HCl, so as to get a
stock solution of 1000 µg/ml concentration.
Standard Solution
20 ml  of  stock  solution  was  made  to  100  ml  with  0.1N HCl,  thus  giving  a
concentration of 200  µg/ml. Aliquot of standard drug solution ranging from 1 to 8 ml
were transferred in to 10 ml volumetric flask and were diluted up to the mark with 0.1N
HCl. Thus the final concentration ranges from 2-16 µg/ml. Absorbance of each solution
was measured at 224.0 nm against 0.1N HCl as a blank. A plot of concentrations of drug
versus absorbance was plotted.
The linear regression analysis was done on absorbance data points.
A straight-line equation was generated to facilitate the calculation of amount of drug.
The equation is as follows.
Y = mx + c
Where Y= Absorbance, m = slope, x = Concentration, c = Intercept.
Preparation of phosphate buffer pH 6.8
Place 50.0 ml of 0.2M potassium dihydrigen phosphate in a 20ml volumetric
flask, add the specified volume of 22.4ml of 0.2M sodium hydroxide and then add water
to make the volume.
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0.2Mpotassium dihydrogen phosphate
Dissolve27.218gm  of  potassium  dihydrogen  phosphate  in  distilled  water  and
dilute to 1000ml with distilled water.
0.2Msodium hydroxide solution
Dissolve 8g of sodium hydroxide in distilled water and dilute to 1000ml with
distilled water.
Preparation of standard drug solution
Stoke solution
100mg of Venlafaxine HCl was dissolved in 100 ml  of  phosphate buffer pH6.8,
so as to get a solution of 1000µg/ml concentration.
Standard solution
20ml of stoke solution was made to 100ml with phosphate buffer  pH6.8,
thus giving a concentration of 200 µg/ml. Aliquot of standard drug solution ranging from
1 to 8 ml were transferred in to 10 ml volumetric flask and were diluted up to the mark
with phosphate  buffer   pH6.8.  Thus the  final  concentration  ranges  from 2-16  µg/ml.
Absorbance of each solution was measured at 224.0 nm against phosphate buffer pH 6.8
as a blank. A plot of concentrations of drug versus absorbance was plotted
                                                  
                                                   Table.5
CALIBRATION CURVE FOR THE ESTIMATION OF VENLAFAXINE HCl  IN 0.1 N HCl
Sl. No Concentration (µg/ml)
Absorbance in 
0.1N HCl
67
1. 0 0
2. 2 0.044
3. 4 0.092
4. 6 0.134
5. 8 0.169
 6. 10 0.206
7. 12 0.260
8. 14 0.304
9. 16 0.332
Slope 0.020966667
Correlation Coefficient 0.998886793
Figure 01
Table.6
CALIBRATION CURVE FOR THE ESTIMATION OF VENLAFAXINE HCL IN PHOSPHATE
BUFFER PH 6.8
Sl. No Concentration (µg/ml)
Absorbance in 
Phosphate
buffer pH 6.8
1. 0 0
2. 2 0..036
3. 4 0.082
4. 6 0.132
5. 8 0.166
 6. 10 0.209
7. 12 0.254
8. 14 0.296
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9. 16 0.342
Slope 0.021408333
Correlation Coefficient 0.999626534
                                                           Figure  02
           7.5 PREPARATIONOFMUCOADHESIVEMICROSPHERES BY
               EMULSION-SOLVENT EVAPORATION TECHNIQUE
Accurately weighed quantity of the polymer (Ethyl Cellulose & Eudragit RS100)
was dissolved in 20 ml of acetone. Weighed quantity of VENLAFAXINE HCl (drug)
and mucoadhesive polymer HPMC K4M (previously passed through the sieve # 150)
were then dispersed in the above polymer phase; and it was stirred for 2 hours. Then it
was emulsified with the 100 ml of liquid paraffin containing 1.0 w/v of Span 80 with
continuous stirring at 800rpm under a magnetic stirrer. The stirring was continued for 2
hours to ensure complete evaporation of acetone. The microspheres were then separated
from liquid paraffin by filtration   through Whatmann filter paper No. 44, washed three
times with 50 ml of petroleum ether, and air dried for 12 hours. All the formulations of
microspheres  were  prepared  in  the  same  way.  The detailed  compositions  of  various
formulations prepared employing 23 factorial designs were mentioned in Table No.7 and
8
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                                                           Table. 7
LEVELS OF FACTORS
Factors Low level High level
Ethyl cellulose 750 1000
HPMC K4M 200 300
Eudragit RS100 100 200
                                                           Table. 8
COMPOSITION OF FORMULATIONS OF MUCOADHESIVE
MICROSPHERES OF VENLAFAXINE HCL
Formulation
Code
Venlafaxine
Hcl
(mg)
EC
(mg)
Eudragit 
RS100 
(mg)
HPMC K4M 
(mg)
F1 500 750 100 200
F2 500 1000 100 200
F3 500 750 200 200
F4 500 1000 200 200
F5 500 750 100 300
F6 500 1000 100 300
F7 500 750 200 300
F8 500 1000 200 300
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7.6 EVALUATION OF THE PREPARED MUCOADHESIVE
MICROSPHERES
7.6.1. DETERMINATION OF PERCENTAGE YIELD OF MICROSPHERES 68
Thoroughly  dried  microspheres  were  collected  and  weighed  accurately.  The
percentage yield was then calculated using formula given below. 
Mass of  microspheres obtained 
% yield =  x 100
Total weight of  drug and polymer
7.6.2. MICROSPHERE SIZE ANALYSIS69
            Microsphere size distribution 
Microsphere size determination was done by optical microscopy method.  Size
distribution plays a very important role in determining the release characteristics of the
microspheres. 
7.6.3. ANGLE OF REPOSE70
The fractional force in the loose powder can be measured by the angle of repose.
This is the maximum angle possible between the surfaces of the site of the powder to the
horizontal plane.
Angle of repose was calculated by static method using funnel. Funnel was kept
on triangular stand, which was kept on horizontal plane. The sample was introduced into
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the funnel, as the pile forms; it reaches to the tip of funnel. The diameter of the pile was
noted. The angle of repose (θ) is calculated by the following formula, 
θ = tan-1 (h/r)
Where, 
h = pile height of microspheres;
r = radius of the circular are formed by the microspheres on the ground.
7.6.4 DETERMINATION OF BULK DENSITY 71
 The bulk density was determined by 3-tap method. Bulk density is defined as,
“the mass of powder divided by the bulk volume”. The packing characteristics of the
powder play an important role in determining physical properties of product. According
to the  standard  procedure  for  obtaining bulk density,  weighed  quantities  of  prepared
microspheres were filled in 10 ml of graduated cylinder the initial volume was noted.
After  tapping  for  three  times  the  final  volume  was  noted.  The  bulk  density  was
calculated as per following formula:   
r  = 
WO
VO
Where,
ρ= Bulk density  
Wo =Weight of sample in gm 
Vo= Final volume after tapping 
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7.6.5.   DETERMINATION OF DRUG CONTENT 72
Accurately weighed 100 mg microspheres, crushed in glass mortar and pestle and
the powdered microspheres were suspended in 100 ml of 0.1N HCl. After 12 hours the
solution was filtered and the filtrate was analyzed for the drug content using UV –Visible
spectrophotometer at 224nm.
7.6.6 ENCAPSULATION EFFICIENCY73
Encapsulation efficiency was calculated using the following formula;
Encapsulation efficiency = 
Estimated drug content %
x100
Theoretical  drug content %
 
 
 
                     
Where, 
Wo = initial weight of the dry microspheres, 
We = weight of the swollen microspheres at equilibrium swelling in the media. 
7.6.7. IN VIVO WASH-OFF TEST74
                 The mucoadhesive property of microspheres was evaluated by an In vitro
adhesion testing method known as wash-off method.  Freshly excised piece of intestinal
mucosa  (2  x  2  cm)  from  goat  were  mounted  on  to  glass  slides  (3  x  1  inch)  with
cyanoacrylate glue. Two glass slides were connected with a suitable support, about 25
microspheres  were  spread  on  to  each  wet  rinsed  tissue  specimen  and  immediately
thereafter  the  support   was  hung  on  to  the  arm of  a  USP  tablet  disintegrating  test
machine. When the disintegrating test machine was operated, the tissue specimen was
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given  slow,  regular  up-and-down  moment  in  the  test  fluid  (900  ml  of  0.1N
HCl/phosphate buffer pH 6.8 at 37 ± 0.5°C. At the end of one hour, and at the hourly
intervals  up  to  5  hours,  the  machine  was  stopped  and  number  of  microspheres  still
adhering to tissue was calculated. The studies were carried out in triplicate. 
Figure. 3
IN VITRO WASH-OFF TEST FOR MUCOADHESION 
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7.6.9 IN-VIVO SISSOLUTION STUDIES76
Dissolution studies  were  carried  out  for  all  the  formulations,  employing  USP
XXIII apparatus (Basket method) at 37 + 0.5°C rotated at constant speed of 50 rpm using
0.1N HCl as the dissolution medium for first 2 hrs and remaining in phosphate buffer pH
6.8. A sample of microspheres equivalent weight to 75 mg of venlafaxine HCl was used
in each  test.  An  aliquot  of  the  sample  was  periodically  with  drawn at  suitable  time
interval  and  the  volumes  were  replaced  with  fresh  dissolution  medium  in  order  to
maintain the sink condition. The sample was analyzed spectrophotometrically at 224nm.
7.6.10. KENETICS OF DRUG RELEASE 77, 81, 82
In  order  to  understand  the  mechanism  and  kinetic  of  drug  release,  the  drug
release data of the  in-vitro  dissolution study were analyzed with various kinetic model
like zero order, first order, Higuchi’s, Peppa’s and Coefficient of correlation (r) values
were calculated for the linear curves by regression analysis of the above plots.
7.6.11. SHAPE AND SURFASE CHARECTERISATION78
The shape and surface characterization of microspheres were observed under a
Scanning  Electron  Microscope  (SEM).  The instrument  used  for  this  study was  Joel
model  JSM  6400,  Tokyo  Scanning  Electron  Microscope.  The  microspheres  were
mounted directly on to the SEM sample stub, using double-sided sticking tape, and
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coated with gold film (thickness 200 nm) under reduced pressure (0.001 torr) and
photographed.
                                        8.0 RESULTS
8.1 PRE FORMULATION STUDIES FOR DRUG AND CARRIER
INTERACTION
a) Fourier Transform Infrared Spectrophotometry (FTIR) 
Infrared  spectra  for  pure  Venlafaxine  HCl  and  for  the  physical  mixture  of
Venlafaxine HCl and all the polymers were determined to check the intactness of the
drug  in  the  polymer  mixture  using  Perkin  Elmer  Spectrum-  RX1   FTIR  -
Spectrophotometer by disc method. The following table shows the wave number for the
characteristic bands in the IR spectra of pure Venlafaxine HCl
Table. 9
Wave number in cm-1 Characteristic bands
2938 Alkane/cyclohexane
1470 Alkane(C-H bending)
829 Aromatic ring
1612 Tertiary amine
3325 O-H stretching
1108,1149 Tertiary amine
1039 Tertiary alcohol
FTIR spectra for pure drug, for the carriers and for the physical  mixture of both are
shown in Figure 4, 5 
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b) Differential scanning colorimeter   (DSC)
DSC thermogram of venlafaxine HCl and physical  mixture of drug and polymers  are
shown in Figure. 6 to 7. DSC thermogram of pure drug has shown a melting endotherm
at 216.6°C with normalized energy. The thermogram of physical mixture showed that the
venlafaxine HCl melting onset temperature decreased to 213.4° C because of the presence
of polymers in the physical mixture.
Figure. 6
DSC Spectra for pure drug of venlafaxine Hcl
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Figure. 7
DSC Spectra for Physical mixture of VenlafaxineHcl + Eudragit RS100+ 
HPMC K4M+EC
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                                                              Table. 10
DATA FOR PERCENTAGE YIELD OF FORMULATIONS OF
MUCOADHESIVE
 MICROSPHERES OF VENLAFAXINE HCL
Formulation code
Percentage yield
(%)
F1 47.10
F2 80.00
F3 76.91
F4 43.68
F5 91.82
F6 48.32
F7 62.06
F8 87.00
Table. 11
SIZE DISTRIBUTION ANALYSIS OF MICROSPHERES FOR F1
81
Size
range
Mid point
Calibration
factor
Particle
size in µm
(x)
Number
of particle
(n)
n*x
Average size
in µm
11-12 11.5 3.33 38.30 5 191.5
65.66
13-14 13.5 3.33 44.96 6 269.8
15-16 15.5 3.33 51.62 12 619.44
17-18 17.5 3.33 58.28 10 582.75
19-20 19.5 3.33 64.94 19 1233.76
21-22 21.5 3.33 71.60
21
1503.50
23-24 23.5 3.33 78.26 19 1486.85
25-26 25.5 3.33 84.92 8 679.32
27-28 27.5 3.33 91.58 0 0
∑n= 100 ∑nx=6566.01
Table. 12
SIZE DISTRIBUTION ANALYSIS OF MICROSPHERES FOR F2
82
Size range Mid point
 
Calibration
factor 
Particle 
size in µm
(x)
Number
of
particle
(n)
n*x
Average size
in µm
13-14 13.5 3.33 44.955 0 0
71.13
15-16 15.5 3.33 51.615 2 103.23
17-18 17.5 3.33 58.275 8 466.20
19-20 19.5 3.33 64.935 25 1623.20
21-22 21.5 3.33 71.595 40 2863.80
23-34 23.5 3.33 78.255
15
1173.83
25-26 25.5 3.33 84.915 5 424.58
27-28 27.5 3.33 91.58 5 457.88
∑n= 100 ∑nx=7112.88
Table 13
SIZE DISTRIBUTION ANALYSIS OF MICROSPHERES FOR F3
83
Size range Mid point
 
Calibration
factor 
Particle 
size in µm
(x)
Number
of
particle
(n)
n*x
Average
size in µm
15-16 15.5 3.33 51.615 0 0
72.17
17-18 17.5 3.33 58.275 6 349.65
19-20 19.5 3.33 64.935 20 1298.70
21-22 21.5 3.33 71.595 50 3570.75
23-34 23.5 3.33 78.255 11 860.81
25-26 25.5 3.33 84.915 8 679.32
27-28 27.5 3.33 91.58 5 457.88
∑n= 100 ∑nx=72171
                          
Table 14
SIZE DISTRIBUTION ANALYSIS OF MICROSPHERES FOR F4
84
Size range Mid point
 
Calibration
factor 
Particle 
size in µm
(x)
Number
of
particle
(n)
n*x
Average
size in µm
15-16 15.5 3.33 51.615 0 0
78.59
17-18 17.5 3.33 58.275 4 233.1
19-20 19.5 3.33 64.935 9 584.42
21-22 21.5 3.33 71.595 15 1073.93
23-34 23.5 3.33 78.255 35 2738.93
25-26 25.5 3.33 84.915 24 2037.96
27-28 27.5 3.33 91.58 13 1190.48
∑n= 100
∑nx=7858
.8
                                                    
Table 15
SIZE DISTRIBUTION ANALYSIS OF MICROSPHERES FOR F5
Size range Mid point  
Calibration
Particle 
size in µm
Number
of
N*x Average
size in µm
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factor (x)
particle
(n)
15-16
15.5
3.33 51.615
0 0 81.92
17-18 17.5 3.33 58.275 0 0
19-20 19.5 3.33 64.935 7 454.55
21-22 21.5 3.33 71.595 10 715.95
23-34 23.5 3.33 78.255 36 2817.18
25-26 25.5 3.33 84.915 20 1698.30
27-28 27.5 3.33 91.575 22 2014.65
29-30 29.5 3.33 98.24 05 493.18
∑n= 100 ∑nx=8192.0
Table 16
SIZE DISTRIBUTION ANALYSIS OF MICROSPHERES FOR F6
Size range Mid point
 
Calibration
factor 
Particle 
size in µm
(x)
Number
of
particle
(n)
N*x
Average
size in µm
15-16 15.5 3.33 51.615 0 0 83.76
17-18 17.5
3.33
58.275
0 0
19-20 19.5 3.33 64.935 4 259.74
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21-22 21.5 3.33 71.595 9 644.36
23-34 23.5 3.33 78.255 29 2269.40
25-26 25.5 3.33 84.915 22 1868.13
27-28 27.5 3.33 91.575 30 2747.25
29-30 29.5 3.33 98.24 6 589.41
∑n= 100 ∑nx=8376.2
                                                           
Table. 17
SIZE DISTRIBUTION ANALYSIS OF MICROSPHERES FOR F7
Size range Mid point
 
Calibration
factor 
Particle 
size in µm
(x)
Number
of
particle
(n)
n*x
Average
size in µm
21-22 21.5
3.33
71.595
10
715.95
100.04
23-34 23.5 3.33 78.255 4 313.02
25-26 25.5 3.33 84.915 5 425.575
27-28 27.5 3.33 91.575 15 1373.625
29-30 29.5 3.33 98.235 11 1080.585
31-32 31.5 3.33 104.895 33 3461.535
33-34 33.5 3.33 111.555 5 557.775
35-36 35.5 3.33 118.215 7 827.505
37-38 37.5 3.33 124.875 10 1248.75
∑n= 100 ∑nx=10004.26
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Table. 18
SIZE DISTRIBUTION ANALYSIS OF MICROSPHERES FOR F8
Size range Mid point
 
Calibration
factor 
Particle 
size in µm
(x)
Number
of
particle
(n)
n*x
Average
size in µm
21-22 21.5 3.33 71.595 2 143.19
105.43
23-34
23.5
3.33
78.255
5 391.275
25-26 25.5 3.33 84.915 2 169.83
27-28 27.5 3.33 91.575 11 1007.325
29-30 29.5 3.33 98.235 12 1178.82
31-32 31.5 3.33 104.895 31 3251.745
33-34 33.5 3.33 111.555 16 1784.88
35-36 35.5 3.33 118.215 7 827.505
37-38 37.5 3.33 124.875 10 1248.75
39-40 39.5 3.33 131.535 4 526.14
∑n= 100 ∑nx=10529.48
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Table 19
THE ARITHMETIC MEAN SIZE ANALYSIS OF MICRO SPHERES
OF VENLAFAXINE HCL
Formula
code
Average
particle size
in µm
F1 65.66
F2 71.13
F3 72.17
F4 78.59
F5 81.92
F6 83.76
F7 100.04
F8 105.30
Table. 20
DATA FOR ANGLE OF REPOSE OF FORMULATIONS OF
89
MUCOADHESIVE MICROSPHERES OF VENLAFAXINE HCL
Formula code
Angle of repose
θ=tan-1(h/r) Mean  ± S.D
(n=3)
F1              26° 21' ± 0.958
F2 24° 22' ± 1.305
F3 25° 20' ± 1.572
F4 24° 10' ± 2.469
F5
22° 53' ± 2.258
F6 23° 25' ± 0.989
F7 22° 12' ± 1.801
F8 25° 11' ± 1.878
Table. 21
DATA FOR BULK DENSITY OF FORMULATIONS OF 
MUCOADHESIVE MICROSPHERES OF VENLAFAXINE HCL
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Formula code
Bulk Density
gm/cm3 ± SD
F1 0.551 ± 0.009
F2 0.561 ± 0.009
F3 0.572 ± 0.016
F4 0.595 ± 0.027
F5 0.531 ± 0.008
F6 0.620 ± 0.029
F7 0.501 ± 0.013
F8 0.501 ± 0.013
Table. 22
DATA FOR PERCENTAGE DRUG CONTENT OF FORMULATIONS OF
 MUCOADHESIVE MICROSPHERES OF VENLAFAXINE HCL
Formula code
Percentage Drug Content
(mean % ± SD)
F1 22.74± 0.060
F2 24.71± 0.540
F3 24.65± 1.406
F4 18.00± 0.040
F5 28.20± 0.045
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F6 19.47± 0.050
F7 25.67± 0.04
F8 73.51± 0.050
Table. 23
DATA FOR PERCENT ENTRAPMENT EFFICIENCY OF FORMULATIONS
MUCOADHESIVE MICROSPHERES OF VENLAFAXINE HCL
Formula
code
Theoretical 
drug content in %
Practical
drug content in %
Entrapment
Efficiency in %
F1 32.26 22.74 70.49
F2 27.78 24.71 88.94
      F3 30.30 24.65 81.35
F4 26.31 18.00 68.38
F5 30.30 28.20 93.08
F6 26.32 19.47 73.97
F7 28.57 25.67 89.86
F8 25.00 18.38 73.51
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Table 24
DATA FOR IN VITRO WASH-OFF TEST FOR MUCOADHESION IN 0.1N HCl
Formula
code
Mean Percentage of microspheres adhering to tissue (n=3)
0.1N Hcl
0.5hr 1hr 2hrs 3hrs 4hrs 5hrs
F1 69.33 (3.33) 66.67 (3.46) 62.67 (3.69) 60.00 (0.00) 58.67 (3.94) 54.67 (4.03)
F2 77.33 (2.99) 73.33 (3.15) 69.33 (3.15) 65.33 (5.53) 62.67 (7.33) 57.33 (4.33)
F3 76.00 (9.12) 70.87 (6.54) 66.67(6.93) 64.00 (6.25) 60.00 (0.00) 54.67 (4.22)
F4 74.67 (3.09) 70.67 (3.27) 68.00 (0.00) 61.33 (3.77) 62.67 (3.69) 48.00 (8.33)
F5 89.73 (2.59) 8067 (5.33) 84.00 (4.76) 78.67 (5.87) 78.67 (2.94) 73.33 (3.15)
F6 84.00 (4.76) 86.67 (5.68) 77.33 (5.97) 78.67 (2.99) 74.67 (3.09) 73.33 (3.15)
F7 85.33 (2.71) 84.00 (4.75) 80.00 (5.00) 78.67 (2.94) 74.67 (3.09) 68.00 (5.85)
F8 86.67 (2.59) 84.00 (0.00) 81.33 (2.84) 78.67 (2.94) 74.67 (3.09) 72.00 (5.56)
Table. 25
DATA FOR IN VITRO WASH-OFF TEST FOR MUCOADHESION IN
PHOSPHATE BUFFER pH 6.8
Formula
code
Mean Percentage of microspheres adhering to tissue (n=3)
Phosphate buffer pH 6.8
0.5hr 1hr 2hrs 3hrs
F1 60.00 (0.00) 54.67 (11.18) 48.00 (8.33) 45.33 (5.09)
F2 65.33 (3.53) 58.67 (3.94) 52.00 (7.69) 46.67 (4.95)
F3 64.00 (6.25) 60.00 (0.00) 54.67 (3.69) 49.33 (4.68)
F4 62.67 3.69) 60.00 (13.33) 50.67 (12.06) 48.00 (8.33)
F5 78.67 (5.87) 70.67 (18.29) 61.33 (12.06) 57.33 (14.77)
F6 77.33(2.99) 74.67 (3.69) 61.33 (13.59) 61.33 (3.79)
F7 80.00 (5.00) 70.67 (2.99) 65.33 (12.74) 58.67 (10.41)
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F8 76.00 (5.26) 73.33 (3.15) 62.67 (13.29) 56.00 (0.00)
Numbers in parenthesis indicates the coefficient of variance (CV) (or) percentage relative
standard deviation (%RSD).
CV = (Standard Deviation / Mean)*100
 Table. 26
IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F1
Time
in
hrs
Cumulative percentage drug release Meam cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0.00 0.00 0±0
1 9.16 9.73 10.30 9.73±0.57
2 16.05 16.62 17.19 16.62±0.57
3 29.22 30.35 31.49 30.35±1.135
4 37.38 38.51 39.65 38.51±1.135
5 43.31 44.44 45.58 44.44±1.135
6 50.09 51.23 52.37 51.23±1.14
7 54.65 55.79 56.93 55.79±1.14
8 57.82 58.96 60.10 58.96±1.14
9 59.88 61.02 62.16 61.02±1.14
10 61.37 62.52 63.66 62.51±1.145
11 63.44 64.58 65.72 64.58±1.14
12 65.78 66.93 68.07 66.92±1.145
13 67.29 68.44 69.59 68.44±1.15
14 69.37 70.51 71.66 70.51±1.145
15 70.04 71.19 72.34 71.19±1.15
16 71.00 72.15 73.30 72.15±1.15
17 72.52 73.67 74.83 73.67±1.155
18 74.05 75.20 76.35 75.2±1.15
19 76.13 77.29 78.44 77.28±1.155
20 79.63 80.78 81.94 80.78±1.155
21 80.61 81.76 82.92 81.76±1.155
22 81.59 82.74 83.90 82.74±1.155
23 84.25 85.41 86.57 85.41±1.16
24 86.64 87.80 88.96 87.8±1.16
    Figure.8
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      Figure .9
Figure .10
95
                                                         Figure .11
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IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F2
Time
in hrs
Cumulative percentage drug release Meam cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0.00 0.00 0±0
1 7.44 8.01 8.59 8.013±0.575
2 14.04 14.61 15.19 14.61±0.575
3 25.53 26.66 27.80 26.66±1.135
4 35.36 36.50 37.64 36.5±1.14
5 40.74 41.87 43.01 41.87±1.135
6 45.84 46.98 48.12 46.98±1.14
7 49.55 50.69 51.83 50.69±1.14
8 51.59 52.74 53.88 52.73±1.145
9 54.20 55.34 56.48 55.34±1.14
10 58.21 59.36 60.50 59.35±1.145
11 59.71 60.85 62.00 60.85±1.145
12 60.93 62.08 63.22 62.07±1.145
13 62.72 63.86 65.01 63.86±1.145
14 64.22 65.37 66.52 65.37±1.15
15 66.30 67.44 68.59 67.44±1.145
16 68.37 69.52 70.67 69.52±1.15
17 70.17 71.32 72.47 71.32±1.15
18 72.26 73.41 74.56 73.41±1.15
19 74.06 75.22 76.37 75.21±1.155
20 75.88 77.03 78.19 77.03±1.155
21 77.13 78.29 79.44 78.28±1.155
22 78.67 79.83 80.98 79.82±1.155
23 82.45 83.61 84.77 83.61±1.16
24 84.56 85.72 86.88 85.72±1.16
Figure.12
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Figure .13
Figure. 14
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                                                   Figure.15
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INVITRO DRUG RELEASE PROFILE FOR FORMULATION F3
Time
in hrs
Cumulative percentage drug release Meam cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0.00 0.00 0±0
1 8.87 9.44 10.02 9.44±0.575
2 16.05 16.62 17.19 16.62±0.575
3 29.22 30.35 31.49 30.35±1.135
4 37.37 38.51 39.65 38.51±1.14
5 40.22 41.36 42.50 41.36±1.14
6 43.36 44.50 45.64 44.5±1.14
7 46.78 47.92 49.06 47.92±1.14
8 51.62 52.76 53.90 52.76±1.14
9 54.78 55.92 57.06 55.92±1.14
10 57.39 58.53 59.67 58.53±1.14
11 59.72 60.86 62.01 60.86±1.145
12 62.06 63.20 64.35 63.20±1.145
13 65.80 66.95 68.09 66.94±1.145
14 67.59 68.74 69.89 68.74±1.15
15 69.39 70.54 71.68 70.53±1.145
16 70.90 72.05 73.20 72.05±1.15
17 72.43 73.58 74.73 73.58±1.15
18 73.67 74.82 75.97 74.82±1.15
19 75.48 76.63 77.78 76.63±1.15
20 77.01 78.16 79.32 78.16±1.155
21 77.98 79.14 80.29 79.13±1.155
22 78.95 80.11 81.27 80.11±1.16
23 80.77 81.93 83.09 81.93±1.16
24 82.31 83.47 84.63 83.47±1.16
                                                       
                                                            Figure .16
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IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F4
Time
in hrs
Cumulative percentage drug release Meam cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0.00 0.00 0±0
1 8.30 8.87 9.44 08.87±0.57
2 11.18 11.75 12.33 11.75±0.575
3 25.19 26.33 27.46 26.32±1.135
4 29.71 30.84 31.98 30.84±1.135
5 33.67 34.81 35.95 34.81±1.14
6 38.77 39.90 41.04 39.90±1.135
7 42.75 43.89 45.03 43.89±1.14
8 47.59 48.73 49.87 48.73±1.14
9 51.87 53.01 54.15 53.01±1.14
10 55.32 56.47 57.61 56.46±1.145
11 56.82 57.97 59.11 57.96±1.145
12 58.04 59.19 60.33 59.18±1.145
13 58.99 60.13 61.28 60.13±1.145
14 60.49 61.64 62.79 61.64±1.15
15 62.28 63.43 64.58 63.43±1.15
16 64.64 65.79 66.94 65.79±1.15
17 66.43 67.59 68.74 67.58±1.155
18 68.80 69.95 71.10 69.95±1.15
19 70.88 72.04 73.19 72.03±1.155
20 72.69 73.85 75.00 73.84±1.155
21 73.95 75.10 76.26 75.10±1.155
22 74.92 76.08 77.24 76.08±1.16
23 75.90 77.06 78.22 77.06±1.16
24 81.65 82.81 83.97 82.81±1.16
                                                       Figure .20
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Figure. 21
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Figure. 23
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IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F5
Time
in hrs
Cumulative percentage drug release Meam cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0.00 0.00 0±0
1 8.87 9.44 10.02 9.443±0.575
2 12.04 12.61 13.19 12.61±0.575
3 27.73 28.87 30.00 28.86±1.135
4 33.09 34.23 35.36 34.22±1.135
5 37.06 38.20 39.34 38.2±1.14
6 41.88 43.02 44.16 43.02±1.14
7 46.15 47.29 48.43 47.29±1.14
8 49.87 51.01 52.15 51.01±1.14
9 53.04 54.18 55.32 54.18±1.14
10 54.53 55.67 56.82 55.67±1.145
11 56.59 57.73 58.87 57.73±1.14
12 58.93 60.07 61.22 60.07±1.145
13 60.43 61.58 62.72 61.57±1.145
14 62.50 63.65 64.79 63.64±1.145
15 63.17 64.32 65.47 64.32±1.15
16 64.12 65.27 66.42 65.27±1.15
17 65.64 66.79 67.94 66.79±1.15
18 69.96 71.11 72.26 71.11±1.15
19 72.04 73.20 74.35 73.19±1.155
20 73.86 75.01 76.17 75.01±1.155
21 76.51 77.67 78.82 77.66±1.155
22 78.33 79.49 80.65 79.49±1.16
23 79.32 80.48 81.63 80.47±1.155
24 81.42 82.58 83.74 82.58±1.16
                                                    
                                                    Figure. 24
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Figure. 26
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IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F6
Time
in hrs
Cumulative percentage drug release Mean cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0.00 0.00 0±0
1 8.87 9.44 10.02 9.443±0.575
2 11.75 12.33 12.90 12.32±0.575
3 25.49 26.62 27.75 26.62±1.13
4 27.48 28.61 29.75 28.61±1.135
5 29.19 30.33 31.47 30.33±1.14
6 34.56 35.70 36.83 35.69±1.135
7 41.90 43.03 44.17 43.03±1.135
8 45.04 46.19 47.33 46.18±1.145
9 49.88 51.02 52.17 51.02±1.145
10 51.93 53.07 54.21 53.07±1.14
11 53.70 54.84 55.99 54.84±1.145
12 55.75 56.90 58.04 56.89±1.145
13 57.25 58.40 59.54 58.39±1.145
14 58.47 59.62 60.77 59.62±1.15
15 59.69 60.84 61.99 60.84±1.15
16 61.48 62.63 63.78 62.63±1.15
17 63.55 64.70 65.85 64.7±1.15
18 67.00 68.15 69.30 68.15±1.15
19 68.55 69.70 70.86 69.70±1.155
20 70.91 72.07 73.22 72.06±1.155
21 72.16 73.32 74.48 73.32±1.16
22 73.98 75.13 76.29 75.13±1.155
23 77.75 78.91 80.07 78.91±1.16
24 79.58 80.74 81.90 80.74±1.16
                                                        
                                                       Figure. 28
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 Figure 29
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IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F7
Time
in hrs
Cumulative percentage drug release Meam cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0.00 0.00 0±0
1 10.02 10.59 11.16 10.59±0.57
2 14.04 14.62 15.19 14.61±0.575
3 30.30 31.43 32.57 31.43±1.135
4 35.38 36.52 37.65 36.51±1.135
5 38.51 39.65 40.78 39.64±1.135
6 42.49 43.63 44.76 43.62±1.135
7 48.16 49.30 50.44 49.3±1.14
8 50.19 51.33 52.48 51.33±1.145
9 52.24 53.38 54.52 53.38±1.14
10 53.72 54.86 56.01 54.86±1.145
11 55.77 56.91 58.06 56.91±1.145
12 57.82 58.97 60.11 58.96±1.145
13 59.32 60.47 61.61 60.46±1.145
14 61.66 62.81 63.96 62.81±1.15
15 65.13 66.28 67.43 66.28±1.15
16 66.08 67.23 68.38 67.23±1.15
17 67.88 69.03 70.18 69.03±1.15
18 70.52 71.67 72.82 71.67±1.15
19 72.04 73.19 74.35 73.19±1.155
20 74.13 75.28 76.44 75.28±1.155
21 75.10 76.26 77.41 76.25±1.155
22 76.63 77.79 78.95 77.79±1.16
23 79.29 80.45 81.61 80.45±1.16
24 81.67 82.83 83.99 82.83±1.16
 
                                                          Figure.32
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Figure. 34
Figure. 35
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IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F8
Time
in hrs
Cumulative percentage drug release Meam cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0 0.00 0±0
1 9.16 9.73 10.30 9.73±0.57
2 14.04 14.62 15.19 14.61±0.575
3 25.53 26.67 27.80 26.66±1.135
4 29.76 31.71 32.03 31.16±1.228
5 32.32 33.46 34.59 33.45±1.135
6 34.32 35.46 36.60 35.46±1.14
7 38.57 39.71 40.85 39.71±1.14
8 43.11 44.25 45.39 44.25±1.14
9 46.82 47.96 49.10 47.96±1.14
10 49.69 50.84 51.98 50.83±1.145
11 52.01 53.16 54.30 53.15±1.145
12 54.06 55.2 56.35 55.20±1.145
13 55.83 56.97 58.12 56.97±1.145
14 60.40 61.55 62.70 61.55±1.15
15 62.19 63.34 64.48 63.33±1.145
16 63.69 64.84 65.99 64.84±1.15
17 64.92 66.07 67.23 66.07±1.155
18 66.71 67.87 69.02 67.86±1.155
19 68.51 69.67 70.82 69.66±1.155
20 70.87 72.03 73.18 72.02±1.155
21 72.68 73.83 74.99 73.83±1.155
22 75.05 76.2 77.36 76.20±1.155
23 77.42 78.58 79.74 78.58±1.16
24 79.24 80.4 81.56 80.4±1.16
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IN VITRO RELEASE KINETIC DATA FOR VENLAFAXINE HCL
MUCOADHESIVE MICROSPHERES
Formula
code
t 80%
Zero order First order Higuchi's Korsmeyer-Peppas
K0 r K1 r r n R
F1 19.8 3.0111 0.92517 -0.0328 -0.9867 0.9833 0.6153 0.9627
F2 22.05 3.0114 0.9413 -0.0307 -0.9899 0.9888 0.6593 0.9656
F3 21.23 2.9960 0.9413 -0.3054 -0.9944 0.9910 0.6193 0.9726
F4 23.27 2.9550 0.9521 -0.0275 -0.9909 0.9913 0.6692 0.9751
F5 20.86 2.9422 0.9491 -0.0285 -0.9913    0.9910 0.6408     0.9698
F6 22.82 2.9382 0.9520 -0.0267 -0.9927    0.9933 0.6576     0.9828
F7 21.75 2.8704 0.9474 -0.0280 -0.9913    0.9919 0.5972     0.9714
F8 23.88 2.9423 0.9503 -0.0270 -0.9967    0.9969 0.6333     0.9901
K0 – Zero order rate constant
K1 – First order rate constant
r – Coefficient of Correlation
n- Diffusion exponent
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Table. 35
Time 
in hrs
Mean
Cumulative 
% drug 
release  of
F1
Mean
Cumulative
% drug 
release of
F2
Mean
Cumulative 
% drug 
release  of
F3
Mean
Cumulative 
% drug 
release  of
F4
Mean
Cumulative 
% drug 
release  of
F5
Mean
Cumulative 
% drug 
release  of
F6
Mean
Cumulative 
% drug 
release  of
F7
Mean
Cumulative 
% drug 
release  of
F8
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 9.73 8.01 9.44 8.87 9.44 9.44 10.59 9.73
2 16.62 14.61 16.62 11.75 12.61 12.33 14.62 14.62
3 30.35 26.66 30.35 26.33 28.87 26.62 31.43 26.67
4 38.51 38.07 39.77 31.04 35.59 29.39 37.50 31.71
5 44.44 41.87 41.36 34.81 38.20 30.33 39.65 33.46
6 51.23 46.98 44.50 39.90 43.02 35.70 43.63 35.46
7 55.79 50.69 47.92 43.89 47.29 43.03 49.30 39.71
8 59.96 52.74 52.76 48.73 51.01 46.19 51.33 44.25
9 61.02 55.34 55.92 53.01 54.18 51.02 53.38 47.96
10 62.52 59.36 58.53 56.47 55.67 53.07 54.86 50.84
11 64.58 60.85 60.86 57.97 57.73 54.84 56.91 53.16
12 66.93 63.08 63.20 59.19 60.07 56.90 58.97 55.20
13 68.44 63.86 66.95 60.13 61.58 58.40 60.47 56.97
14 70.51 65.37 68.74 61.64 63.65 59.62 62.81 61.55
15 71.19 67.44 70.54 63.43 64.32 60.84 66.28 63.34
16 72.60 70.20 72.05 65.79 65.27 62.63 67.23 64.84
17 73.67 71.32 73.58 67.59 66.79 64.70 69.03 66.07
18 75.20 73.41 74.82 69.95 71.11 68.15 71.67 67.87
19 77.29 75.22 76.63 72.04 73.20 69.70 73.19 69.67
20 80.78 77.03 78.16 73.85 75.01 72.07 75.28 72.03
21 81.76 78.29 79.14 75.10 77.67 73.32 76.26 73.83
22 82.74 79.83 80.11 76.08 79.49 75.13 77.79 76.20
23 85.41 83.61 81.93 77.06 80.48 78.91 80.45 78.58
24 87.80 85.72 83.47 82.81 82.58 80.74 82.83 80.40
COMPARATIVE CUMULATIVVE % DRUG RELEASE PROFILE OF F1-F8
Figure. 40
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SCANNING ELECTRON MICROGRAPH (SEM) OF THE PREPARED
MUCOADHESIVE MICROSPHERES OF VENLAFAXINE HCL
FORMULATION
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Figure. 41
Figure. 42
Figure. 43
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SURFACE VIEW OF THE PREPARED MUCOADHESIVE MICROSPHERES
8. 1 Statistical Optimization technique
The  optimization  phase  was  designed  statistically  using  23 factorial  design  in
which three variables namely concentrations of polymers such as EC, Eudragit RS100
and HPMC K4M were kept at two levels. Except the optimization phase whose purpose
was validated by extra design check point and main interactive influences were tested
using statistical methods. The eight formulations of optimization phase were categorized
in to four groups for ease of analysis and comparison as follows:
1. Group I : All variables at low level (Formulation F1).
2. Group II : Any one of three variables at high level (Formulations F2, F3, F5).
3. Group III : Any two of three variables at high level (Formulations F4, F6, F7).
4. Group IV : All three variables at high level (Formulation F8). 
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Although all formulation were analyzed for uniformity of release pattern, amount
of drug release at the end of 24 hours, and mechanism of drug release, and all of these
parameters were considered for selection of best formulation in the optimization phase,
only release rate and t80%  values were used for comparative analysis as they characterize
the entire kinetic profile.
Compare  to  base  line  response  of  Group-I  formulation  the  t80% values  of  all
formulations in Group-II  were relatively high.  It  indicates that  every polymer has the
ability to sustain and retard the release at high concentration, though the magnitude of
their  impact  was  chiefly  indicated  by their  extent  of  solubility  and  swellability.  The
formulation F2, F3 and F5 contains higher proportion of EC, Eudragit RS100 and HPMC
K4M respectively.  Based  on  the  t80%  value  of  the  above  formulations,  the  degree  of
retardency is in the order of EC > HPMC K4M >Eudragit RS100.
The formulation F4, F6 and F7 containing any two of three polymer in higher 
concentration namely Eudragit RS100 & EC, HPMC K4M & EC and Eudragit RS100& 
HPMC K4M. The observed t80% value demonstrated the influence in retarding the release 
as follows HPMC K4M & EC > Eudragit RS100 & EC > Eudragit RS100 & HPMC 
K4M. The formulation F8 containing three polymers in high concentration showed the. 
t80% value of 23.88 hours    
                                                               
                                                              Table: 34
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Formula
Code
Venlafaxine
HCl (mg)
EC
(mg)
Eudragit
RS100
(mg)
HPMC
K4M
(mg)
T80%
(hrs)
Response
F1 500 750      100       200 19.8 Y1
F2 500 1000      100       200 22.05 Y2
F3 500 750      200       200 21.23 Y3
F4 500 1000      200       200 23.27 Y4
F5 500 750      100       300 20.86 Y5
F6 500 1000      100       300 22.82 Y6
F7 500 750      200       300 21.75 Y7
F8 500 1000      200       300 23.88 Y8
                              
                                                       MAIN EFFECTS
Effect of EC    = ((Y2-Y1) + (Y4-Y3) + (Y6-Y5) + (Y8-Y7)) / 4
        = ((22.05-19.8) + (23.27-21.23) + (22.82-20.86) + (23.88-21.75) / 4
     = +2.095
Effect of Eudragit RS100 = ((Y3-Y1) + (Y4-Y2) + (Y7-Y5) + (Y8-Y6)) / 4
                                  = ((21.23-19.80) + (23.27-22.05) + (21.75-20.86) + (23.88-     
.                                           22.82 )) / 4        
             = +1.15
 Effect of HPMC K4M      = ((Y5-Y1) + (Y6-Y2) + (Y7-Y3) + (Y8-Y4)) / 4
            = ((20.86-19.80) + (22.82-22.05) + (21.75-21.23) + (23.88-    
.                                             23.27)) /4                        
                                             = +0.74
124
Effect of EC x EUDRAGIT RS100  
                      High level (+) = ((Y4-Y3) + (Y8-Y7)) / 2
                                              =   ((23.27-21.23) + (23.88-21.75) / 2
                                              = 2.085
Low level (-) = ((Y2-Y1) + (Y6-Y5)) / 2
                                              = ((22.05-19.80) + (22.82-20.86)) / 2
                                              = 2.105
Effect of HPMC x EC
 
High level    = ((Y8-Y4) + (Y7-Y3)) / 2
                                      = ((23.88-23.27) + (21.75-21.23)) / 2
                                      = 0.565
Low level     = ((Y6-Y2) + (Y5-Y1)) / 2
                                     = ((22.82-22.05) + (20.86-19.80)) / 2 
                                             = 0.915
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Effect of HPMC K4M x EUDRAGIT RS100  
           High level     = ((Y6-Y2) + (Y8-Y4)) / 2
                                      = ((22.82-22.05) + (23.88-23.27)) / 2
                                      = 0.69
Low level      = ((Y5-Y1) + (Y7-Y3)) / 2
                                       = ((20.86-19.80) + (21.75-21.23)) / 2
                                       = 0.79
Effect of  EC x EUDRAGIT RS100x HPMC 
           High level     = ((Y8-Y7) + (Y6-Y5)) / 2
                                       = ((23.88-21.75) + (22.82-20.86)) / 2
                                       = 2.045
                      Low level        = ((Y4-Y3) + (Y2-Y1)) / 2 
 
                                       = ((23.27-21.23) + (22.05-19.80)) / 2
                                       = 2.145
EC x HPMC =1/2 difference
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                                           = (High level – low level) / 2
                                          = (0.565-0.915) / 2
                                 
                                           = -0.175
HPMC x EUDRAGIT RS100 = 1/2 difference
                                       = (High level – low level)/2
                                       = (0.69-0.79) / 2 = -0.05
EUDRAGIT RS100 x EC = 1/2 difference
                                        = (High level – low level)/2
      
                                        = (2.085-2.105)/2
                                        = -0.01
EUDRAGIT RS100 x HPMC x EC = 1/2 difference
                                  = (High level – low level) / 2
                                              = (2.045-2.145) / 2
                                              = -0.050
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All these interpretations and implications of polymer characteristics over release
profile were supported statistically and the results of main effects, interactive (two and
three way) effects, were enlisted in Table. 35
                                                       
                                                     Table. 35
EFFECT ESTIMATE
Average +23.1
Main effects
Effect of EC +2.095
Effect of Eudragit RS100 +1.15
Effect of HPMC K4M +0.74
Two factor interactions
Eudragit RS100 X HPMC
K4M
-0.05
HPMC K4M X EC -0.175
Eudragit RS100 X EC -0.01
Three factor Interactions
Eudragit RS100 X HPMC
K4M X EC
-0.50
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The drug release was retarded  by increasing the polymer concentration  due to
increased viscosity and strength of gel  matrix formed due to EUDRAGIT RS100 and
HPMC K4M and low water permeability of EC. This swelling of EUDRAGIT RS100 is
independent on medium pH, which forms hydrogen bonds with imbibing water and also
holds water inside the gel matrix. Increasing the amount of HPMC K4M also forms a gel
network and there the drug diffusion is controlled by penetration of liquid through the
gelled network and there by increasing the t80% value. 
Since the design was optimized statistically using 23 factorial designs it is possible
to authenticate the design by selecting an extra design check point residing within the
influential matrix space and verifying the proximity of predicted response to the observed
one. This was done by constructive polynomial equation of linear interactive model type
using pertinent statistical calculations listed in following pages.
Table: 36
YATES ALGORITHM
Signs to calculate effects in a 23 Factorial Experiment
Factor 
Combination
Level of Factor in
Experiment
Interaction
Total
X1 X2 X3 X1X2 X1X3 X2X3 X1X2X3
F1 -1 -1 -1 1 1 1 -1 -1
F2 1 -1 -1 -1 -1 1 1 1
F3 -1 1 -1 -1 1 -1 1 1
F4 1 1 -1 1 -1 -1 -1 1
F5 -1 -1 1 1 -1 -1 1 1
F6 1 -1 1 -1 1 -1 -1 1
F7 -1 1 1 -1 -1 1 1 1
F8 1 1 1 1 1 1 1 1
+ factor at high level 
- factor at low level
Multiply signs of factors to obtain
signs  for interaction terms in
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combination
Basic Polynomial equation
Y = B0 + B1(x1) + B2 (x2) + B3(x3) + B12 (x1x2) + B13 (x1x3) + B23 (x2x3) + B123 (x1x2x3)
Calculation of coefficient                                                                                        
B0    =   ((1)*(Y1) + (1)*(Y2) + (1)*(Y3) + (1)*(Y4) + (1)*(Y5) +
             (1)*(Y6) + (1)*(Y7) + (1)*(Y8)) / 8    
                    =   ((1*19.80) + (1*22.05) + (1*21.23) + (1*23.27) + (1*20.86) +
             (1*22.82) + (1*21.75) + (1*23.88)) / 8
                =   21.9575
         B1       =   ((-1)*(Y1) + (1)*(Y2) + (-1)*(Y3) + (1)*(Y4) + (-1)*(Y5) +
                         (1)*(Y6) + (-1)*(Y7) + (1)*(Y8)) / 8
            =   {(-1)*( 19.80) + (1)*( 22.05) + (-1)*( 21.23) + (1)*( 23.27) + 
                         (-1)*( 20.86) + (1)*( 22.82) + (-1)*( 21.75) + (1)*( 23.88)} / 8
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             =   1.0475
         
B2        =  ((-1)*(Y1) + (-1)*(Y2) + (1)*(Y3) + (1)*(Y4) + (-1)*(Y5) +
                      (-1)*(Y6) + (1)*(Y7) + (1)*(Y8)) / 8
                   = ((-1)*(19.80) + (-1)*(22.05) + (1)*(21.23) + (1)*(23.27) + (-1)*(20.86) +
                       (-1)*(22.82) + (1)*(21.75) + (1)*(23.88)) / 8
             =   0.575
           B3        =   ((-1)*(Y1) + (-1)*(Y2) + (-1)*(Y3) + (-1)*(Y4) + (1)*(Y5) + 
        (1)*(Y6) + (1)*(Y7) + (1)*(Y8)) / 8
 
           =
   
((-1)*(19.80) + (-1)*(22.05) + (-1)*(21.23) + (-1)*(23.27) + (1)*(20.86) + 
           (1)*(22.82) + (1)*(21.75)+(1)*(23.88)) / 8
           =   0.37
        
B12   = ((1)*(Y1) + (-1)*(Y2) + (-1)*(Y3) + (1)*(Y4) + (1)*(Y5)+
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                     (-1)*(Y6) + (-1)*(Y7) + (1)*(Y8)) / 8
             = ((1)*(19.80)+(-1)*(22.05)+(-1)*(21.23)+(1)*(23.27)+(1)*(20.86)+
                       (-1)*(22.82)+(-1)*(21.75) + (1)*(23.88)) / 
              = -0.005
          B13      =  ((1)*(Y1)+(-1)*(Y2)+(1)*(Y3)+(-1)*(Y4)+(-1)*(Y5)+
                     (1)*(Y6) + (-1)*(Y7)+(1)*(Y8)) / 8
                   =  ((1)*(19.8)+(-1)*(22.05)+(1)*(21.23)+(-1)*(23.27)+
                      (-1)*(20.86)+(1)*(22.82)+ (-1)*(21.75) + (1)*(23.88)) / 8
                   = -0.025
B23  = ((1)*(Y1)+(1)*(Y2)+(-1)*(Y3)+(-1)*(Y4)+(-1)*(Y5)+
                       (-1)*(Y6) + (1)*(Y7) + (1)*(Y8)) / 8
                   = ((1)*(19.8) + (1)*(22.05) + (-1)*(21.23) + (-1)*(23.27) + (-1)*(20.86)+
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                       (-1)*(22.82) + (1)*(21.75)+(1)*(23.88)) / 8
                   = -0.0875
B123 = ((-1)*(Y1) + (1)*(Y2) + (1)*(Y3) + (-1)*(Y4) + (1)*(Y5) + 
                         (1)*(Y6) + (1)*(Y7) + (1)*(Y8)) / 8
                    = ((-1)*(19.8) + (1)*(22.05) + (1)*(21.23) + (-1)*(23.27) + (1)*(20.86) + 
                          (1)*(22.82) + (1)*(21.75) + (1)*(23.88)) / 8
                     = 5.485
Apply the above values in the basic polynomial equation.
Let us consider transformed values
 x1  = 0.5
x2  = 0.5
x3  = 0.5
Actual polynomial Equation
      Y = (21.9575) + (1.0475)(0.5) + (0.575) (0.5) + (0.37 )(0.5) + (-0.005)(0.5*0.5) + 
(-0.025)(0.5*0.5) + (-0.0875) (0.5*0.5) + (5.485) (0.5*0.5*0.5) 
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     = 23.416875
CALCULATION FOR CHANGING THE TRANSFORMED PROPORTIONS TO
THE ACTUAL POLYMER COMPOSITION
Table. 37
Signs to calculate effects in a 23 Factorial Experiment
Factor Low level High level Average
1/2 of difference
of two values
EC 750 1000 875 125
EUDRAGIT RS100 100 200 150 50
HPMC K4M 200 300 250 50
Average = (low level+ high level) / 2
½ of the difference of two values = (High level- low level) / 2
        Transformed value =        x – Average of two values      
                                                                                    One half of difference of two values  
x1 =Conc. of EC
x2 = Conc. of EUDRAGIT RS100
x3= Conc. of HPMC K4M
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For EC
                      x1 –875     =   0.5  
                         125
           
   x1 =  937.5
For EUDRAGIT RS 100
                       x2 -150      =  0.5
                         50
             
 x2 = 175
For HPMC K4M
                        
                         x3 -250    = 0.5        
                            50    
                  x3  = 275
Variables in extra design check point 
x1 = 937.5mg of EC
x2 = 175mg of EUDRAGIT RS100
x3  = 275mg of HPMC K4M
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                                                          Table. 38
IN VITRO DRUG RELEASE DATA FOR EXTRA DESIGN CHECK POINT OF *F9- 1
Time
in hrs
Absorbance
Concentration
in µg/ml
Amount
released in
mg/ml
Cumulative
 amount
released in
900ml(mg)
Cumulative 
% drug 
release 
0 0.000 0.0000 0.0000 0.0000 0.00
1 0.033 1.5739 0.0079 7.0827 9.44
2 0.071 3.3863 0.0169 15.2542 20.34
3
0.032 1.4947
0.0075
21.9806 29.31
4 0.054 2.5224 0.0126 26.6199 35.49
5 0.071 3.3165 0.0166 30.2185 40.29
6 0.082 3.8303 0.0192 32.5638 43.42
7 0.096 4.4842 0.0224 35.5449 47.39
8 0.115 5.3717 0.0269 39.5835 52.78
9 0.122 5.6987 0.0285 41.1086 54.81
10 0.133 6.2125 0.0311 43.4778 57.97
11 0.141 6.5862 0.0329 45.2215 60.30
12 0.147 6.8665 0.0343 46.5486 62.06
13 0.152 7.1000 0.0355 47.6682 63.56
14 0.155 7.2402 0.0362 48.3698 64.49
15 0.161 7.5204 0.0376 49.7034 66.27
16 0.163 7.6139 0.0381 50.1990 66.93
17 0.169 7.8941 0.0395 51.5363 68.72
18 0.174 8.1277 0.0406 52.6663 70.22
19 0.180 8.4079 0.0420 54.0087 72.01
20 0.188 8.7816 0.0439 55.7744 74.37
21 0.195 9.1086 0.0455 57.3336 76.44
22 0.200 9.3422 0.0467 58.4757 77.97
23 0.203 9.4823 0.0474 59.1997 79.93
24
0.212 9.9027 0.0495 61.1863 83.04
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                                                   Figure. 44
Figure. 45
Invitro release of Venlafaxine HCl from 
                  Formulation F9-1
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                                                                   Figure. 46
                                                              Figure. 47
Higuchi plot of formulation F9-1
Korzemayer peppas plot for formulation
F9-1
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                                                      Table. 39
IN VITRO DRUG RELEASE DATA FOR EXTRA DESIGN CHECK POINT OF *F9- 2
Time 
in hrs
Absorbance
Con.
in mg/ml
Amount
released in
mg
Cumulative
 amount
released in 
mg
Cumulative 
% drug 
release
0 0.000 0.0000 0.0000 0.0000 0.00
1 0.033 1.5739 0.0079 7.0827 9.44
2 0.072 3.4340 0.0172 15.4688 20.63
3 0.034 1.5882 0.0079 22.6156 30.15
4 0.053 2.4757 0.0124 26.6252 35.50
5 0.071 3.3165 0.0166 30.4336 40.58
6 0.080 3.7369 0.0187 32.3585 43.14
7 0.095 4.4375 0.0222 35.5489 47.40
8 0.112 5.2316 0.0262 39.1666 52.22
9 0.120 5.6053 0.0280 40.9005 54.53
10 0.130 6.0724 0.0304 43.0586 57.41
11 0.140 6.5395 0.0327 45.2213 60.30
12 0.143 6.6796 0.0334 45.9173 61.22
13 0.152 7.1000 0.0355 47.8758 63.83
14 0.158 7.3803 0.0369 49.2080 65.61
15 0.161 7.5204 0.0376 49.9124 66.55
16 0.163 7.6139 0.0381 50.4080 67.21
17 0.167 7.8007 0.0390 51.3250 68.43
18 0.171 7.9875 0.0399 52.2438 69.66
First order plot for formulation F9-1
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19 0.180 8.4079 0.0420 54.2154 72.29
20 0.184 8.5948 0.0430 55.1403 73.52
21 0.192 8.9685 0.0448 56.9078 75.88
22 0.200 9.3422 0.0467 58.6791 78.24
23 0.201 9.3889 0.0469 58.9827 79.64
24 0.213 9.9494 0.0497 61.5990 83.55
                                                
                                                      Figure. 48
                                              Figure. 49
Invitro release of VenlafaxineHCl from
Formulation F9-2
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                                                        Figure. 50
                                           
Higuchi plot of formulation F9-2
Korzemayer peppas plot for 
formulation F9-2
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                                                   Figure. 51
                                                      Table 40
IN VITRO DRUG RELEASE DATA FOR EXTRA DESIGN CHECK POINT OF *F9- 3
Time 
in hrs
Absorbance
Con.
in mg/ml
Amount
released in
mg
Cumulative
 amount
released in 
mg
Cumulative 
% drug 
release
0 0.000 0.0000 0.0000 0.0000 0.00
1 0.035 1.6693 0.0083 7.5119 10.02
2 0.072 3.4340 0.0172 15.4698 20.63
3 0.035 1.6349 0.0082 22.8267 30.44
4 0.054 2.5224 0.0126 26.8369 35.78
5 0.073 3.4099 0.0170 30.8559 41.14
6 0.085 3.9704 0.0199 33.4123 44.55
7 0.096 4.4842 0.0224 35.7642 47.69
8 0.117 5.4652 0.0273 40.2232 53.63
9 0.125 5.8388 0.0292 41.9595 55.95
10 0.135 6.3060 0.0315 44.1199 58.83
11 0.142 6.6329 0.0332 45.6543 60.87
12 0.147 6.8665 0.0343 46.7716 62.36
13 0.157 7.3336 0.0367 48.9423 65.26
14 0.161 7.5204 0.0376 49.8564 66.48
15 0.165 7.7073 0.0385 50.7724 67.70
16 0.168 7.8474 0.0392 51.4801 68.64
17 0.171 7.9875 0.0399 52.1891 69.59
18 0.174 8.1277 0.0406 52.8996 70.53
First order plot for formulation F9-2
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19 0.181 8.4547 0.0423 54.4523 72.60
20 0.189 8.8283 0.0441 56.2184 74.96
21 0.195 9.1086 0.0455 57.5679 76.76
22 0.199 9.2954 0.0465 58.4998 78.00
23 0.203 9.4823 0.0474 59.4335 79.24
24 0.214 9.9961 0.0500 61.8405 82.76
                                                      Figure 52
                            
                                                      Figure. 53
In vitro release of Venlafaxine HCl from
Formulation F9-3
Higuchi plot of formulation F9-3
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                                                   Figure. 54
                                                
Korzemayer peppas plot for formulation
F9-3
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                                                         Figure. 55
                                                         Table. 41
INVITRO DRUG RELEASE PROFILE OF EXTRA DESIGN CHECK POINT
Time
in hrs
Cumulative percentage drug release Meam cumulative %
drug release ±SD
Trial 1 Trial 2 Trial 3
0 0.00 0 0.00 0±0
1 9.16 9.73 10.30 9.73±0.57
2 14.04 14.62 15.19 14.61±0.575
3 25.53 26.67 27.80 26.66±1.135
4 29.76 31.71 32.03 31.16±1.228
5 32.32 33.46 34.59 33.45±1.135
6 34.32 35.46 36.60 35.46±1.14
7 38.57 39.71 40.85 39.71±1.14
8 43.11 44.25 45.39 44.25±1.14
9 46.82 47.96 49.10 47.96±1.14
10 49.69 50.84 51.98 50.83±1.145
11 52.01 53.16 54.30 53.15±1.145
12 54.06 55.2 56.35 55.20±1.145
13 55.83 56.97 58.12 56.97±1.145
14 60.40 61.55 62.70 61.55±1.15
15 62.19 63.34 64.48 63.33±1.145
First order plot for formulation F9-3
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16 63.69 64.84 65.99 64.84±1.15
17 64.92 66.07 67.23 66.07±1.155
18 66.71 67.87 69.02 67.86±1.155
19 68.51 69.67 70.82 69.66±1.155
20 70.87 72.03 73.18 72.02±1.155
21 72.68 73.83 74.99 73.83±1.155
22 75.05 76.2 77.36 76.20±1.155
23 77.42 78.58 79.74 78.58±1.16
24 79.24 80.4 81.56 80.4±1.16
Table. 42
 IN VITRO RELEASE KINETIC DATA FOR  EXTRA DESIGN CHECK POINT
Formula
code
t 80%
Zero order First order Higuchi's
Korsmeyer-
Peppas
K0 r K1 r r n r
F9-1 23.12 2.7948 0.94017 -0.02741 -0.9897 0.9833 0.5833 0.9741
F9-2 22.98 2.8082 0.9393 -0.0271 -0.9900 0.9888 0.5839 0.9736
F9-3 23.20 2.8120 0.9353 -0.274 -0.9888 0.9910 0.5756 0.9746
Figure. 56
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Table. 43
STUDENT T TEST ON EXTRA DESIGN CHECK POINT
Trial code Predicted T80 Estimated T80
1 23.42 23.12
2 23.42 22.98
3 23.42 23.20
                     P Value = 0.019037 ( <0.05 )
                                                                            
Having  designed  using  appropriate  statistical  calculations,  the  polynomial
equation was used to predict the response that would fulfill the aim of the present study.
COMPARATIVE DRUG RELEASE PROFILE
OF F9-1,F9-2,F9-3
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By  calculating  actual  polymer  concentration  from  transformed  proportions  of  each
variable, the extra design checkpoint formulation was designed. Predicted to exhibit t80%
of 23.42 hours, the extra design checkpoint batch was observed to have t80% of 23.12,
22.98, 23.20 hours. The statistical insignificance of the difference between the predicted
and observed  responses  (P<0.05  OF student  T  test  shows  95% confidence)  not  only
validate  the  design  adopted  for  optimization  but  also  confirms  usefulness  of  the
polynomial equation in predicting the in vitro kinetic parameters.
                                          Table. 44
                         
f2SIMILARITYFACTORSOFFORMULATIONSOFMUCOADHESIVE
                MICROSPHERES OF VENLAFAXINE HCL                                     
                                                                           
FORMULATION
CODE
       f2
SIMILARITY
FACTOR 
          F1       64.42
          F2       80.78
          F3      76.33
          F4      77.38
          F5      88.75
          F6      66.86
          F7      86.80
          F8      66.11
The formulation F5 (, EC-750 mg Eudragit RS100-100 mg, HPMC K4M-300 mg)
was selected as optimized formulation with 82.58% of drug release at 24th hours.
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                                             9.0 DISCUSSION
Venlafaxine HCL is serotonine-epinephrine reuptake inhibitor; a potent drug for
depressive disorders and anxiety. The oral route is preferred for Venlafaxine HCl but it
has  only  12.6%  oral  bioavailability  due  to  high  first  pass  metabolism,  and  the
conventional dosage forms are not recommended because of  shorter half life of 5 Hrs  
In  this  present  work  efforts  have  been  made  to  develop  mucoadhesive
microspheres  of  Venlafaxine HCl using emulsion solvent  evaporation technique using
Ethyl  Cellulose,  Eudragit  RS100  along  with  mucoadhesive  polymer  Hydroxy  Propyl
Methyl Cellulose K4M. The polymer concentration is the major factor controlling drug
release and mucoadhesion 
The FTIR spectral analysis showed that there was no appearance or disappearance
of any characteristic peaks of pure drug Venlafaxine HCl in the physical mixture of drug
and  polymer,  which  confirms  the  absence  of  chemical  interaction  between  drug  and
polymers. The DSC spectral analysis also reveals the same.
The percentage  yield  of  microspheres  of  all  formulations  was in  the  range  of
43.68% to 91.82%. The microsphere prepared by this method was found to be discreet,
spherical,  free  flowing and it  was observed by Scanning Electron Microscopy (SEM)
Figures.41,42,43. The microspheres were uniform in size with a size range of 65.60µm to
105.30µm. The angle of repose revealed that the microspheres of all the batches had good
flow characteristics and flow rates. Table 20.  The bulk density was in the range of 0.4880
to 0.5913 were shown in Table 21
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The  drug  content  determination  showed  that  even  if  the  polymer
composition was changed the process was highly efficient to give microspheres having
maximum drug loading. Table 22. The entrapment efficiency was in the range of 68.38%
to  93.08%.  Table  No  23.Microspheres  of   Venlafaxine  HCl   exhibited  good
mucoadhesive properties in the in vitro wash of test .The test result of wash off test were
shown in the Table 24,25 The F5 formulation has more adhesive strength than others. The
prepared tablets were then subjected to dissolution test for evaluating the in vitro drug
release. The dissolution studies were carried out in 900 ml phosphate buffer pH 6.8 in
USP basket type dissolution apparatus  at 50 rpm and 37 ± 0.5O C. The results of the
dissolution studies indicate that the polymer concentration is having a substantial effect
on the drug release from the microspheres. The invitro drug release was found to be 80.4
to 87.89(Table 26 to 33)
The statistical analysis of the factorial design batches was performed by multiple
linear regression analysis using Microsoft Excel. The results depicted in Table 36 clearly
indicate that the response Y is strongly dependent on the selected independent variables,
as shown by the wide variation among the 8 batches (F1-F8). The polynomial equation
was  used  to  predict  the  response  that  would fulfill  the  aim of  the  present  study.  By
calculating actual polymer concentration from transformed proportions of each variable,
the extra design checkpoint formulation was designed. Predicted to exhibit t80%  value of
23.42, the extra design checkpoint batch was observed to have t80% value of the 23.12,
22.98 and 23.20 hrs in the three trials respectively (Table. 43).  
The  observed  t80% was  then  compared  with  the  predicted  response  by  using
student’s t test. The p value of the students t test was found to be 0.0190, this statistical
insignificance of the difference between the predicted and observed responses not only
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validate  the  design  adopted  for  optimization  but  also  confirms  usefulness  of  the
polynomial equation in predicting the in vitro kinetic parameters.
Along with the closeness of the t80% of the formulation batches to that of the extra
design check point batch, similarity factor  f2 was also used for the purpose of selecting
the optimized formulation. Out of all of the batches, formulation F5 with low levels of
X1,X2,and high level of X3 was having maximum f2  value of 88.75. Also formulation
F5was having t80% of 20.86, which is the closest among all the formulations to the t80% of
the extra design checkpoint batch. Based on these results we can say that Formulation F5
was found to be the optimized formulation.
In  order  to  understand  the  complex  mechanism  of  drug  release  from  the
mucoadhesive microspheres,  the  in vitro Venlafaxine Hcl. release data were  fitted to
korsmeyer-peppa’s  release  model  and  interpretation  of  release  exponent  values  (n)
enlightens in understanding the release mechanism from the dosage form. The release
exponent values thus obtained were ranged from 0.5763 to 0.6692are shown in Table.34.
All the formulations exhibited anomalous (non-fickian transport) diffusion mechanism.
The drug release was diffusion controlled as the plot of Higuchi’s model was found to be
linear (r > 0.983). These formulations are also showed as highest ‘r ’ values of first  order
kinetics indicating the Venlafaxine HCl. release from these mucoadhesive microspheres
were by diffusion. 
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9.0 CONCLUSION
Mucoadhesive  microspheres  had  shown  excellent  bioavailability  and  loading
efficiency with Venlafaxine HCl.  The polymer concentration is a major factor affecting
the  release  and  mucoadhesion  strength  of  the  prepared  microspheres.  The  observed
response (t80%) is close agreement with the predicted t80% value there by demonstrating the
feasibility  of  the  optimization  procedure  in  developing  mucoadhesive  microspheres
containing  All  the  formulations  exhibited  anomalous  (non-fickian  transport)  diffusion
mechanism and follow first  order kinetic.  The formulation with EC-750 mg,  Eudragit
RS100 100 mg and HPMC K4M-300 mg was selected as optimized formulation; with
82.58% of drug release at 24th hours.
Finally  it  is  concluded  that  with  limited  number  of  experiments  an  optimized
formulation  with  target  release  and  good  mucoadhesion  can  be  developed  with
appropriate statistical experimental design.  
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